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ABSTRACT
The primary focus of tissue engineering is to develop biological substitutes
capable of restoring, maintaining, or improving native tissue function. This field
advances an exciting array of solutions for organ repair and wound healing. In the United
States alone over 6.5 million people are affected by chronic wounds every year, which
account for over $25 billion of healthcare expenses. Vascularization and fast anastomosis
with the host are essential in engineering cellular constructs that survive once implanted.
In the last decade, there has been extensive investigation into fabrication techniques to
create tissue replacements that are rapidly perfused post-implantation to address this
issue.
Three-dimensional bioprinting is a methodology used for generating 3D
constructs of various sizes and shapes from a digital model using a layer-by-layer
approach. These digital models can be derived from patient images, such as CT and MRI
scans, to produce patient-specific tissue replacements. The fabrication of biomimetic
constructs plays an essential role in the advancement of tissue engineering, and provides
the ability to form 3D constructs that are able to recapitulate the in vivo structure and
function of complex tissues. The Palmetto Printer, developed at the Medical University of
South Carolina, is a custom-built multi-dispenser system that uses programmable robotic
manufacturing methods to generate 3D heterogeneous tissue constructs. The assessment
of the Palmetto bioprinter showed high cell viability (>95%) and significant cell
proliferation within the printed constructs over 8 days. Therefore, this technique proves
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its ability to generate scaffolds that allow cell growth, communication, and the formation
of networks; each a requirement of vascularization.
Scaffold-free tissue engineering aims to produce physiologically-relevant 3D
multicellular constructs through the process of cellular self-assembly. We have developed
a scaffold-free prevascular implant model with dense endothelial networks surrounded by
extracellular matrix, similar to capillary vasculature. Upon implantation, we found that
the host rapidly endothelialized these constructs (<6hr), and were perfused by 72 hours
post-implantation. We have demonstrated that this technology can be modified by growth
factors and can be scaled up into larger, more complex geometries. Furthermore,
bioprinter fabrication could allow the creation of personalized implants.
As an application for these fabrication techniques, we developed a novel wound
dressing for the treatment of chronic wounds. The Smart Wound Dressing is a multicomponent device made up of three separate layers that individually address different
facets of the chronic wound environment. This combinatorial approach will provide an
exciting new option for the treatment of these non-healing wounds.
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CHAPTER ONE
OVERVIEW OF TISSUE ENGINEERING TECHNIQUES
The primary focus of tissue engineering is to bridge the gap between organ
shortages and transplantation needs by developing biological substitutes capable of
restoring, maintaining, or improving native tissue function (1-2). As of 2017, in the
United States alone, there were almost 116,000 patients on the organ transplant waiting
list at years end, and only 16,473 recovered donors (3). The number of people on the
waiting list has been rapidly increasing, while the number of donors and transplants has
remained relatively constant since 1990 (Figure 1.1, 3). There is a significant
disproportion between the supply and demand for organ transplants that must be
improved.
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Tissue engineering and regenerative medicine aims to alleviate this organ shortage crisis
through the fabrication of functional tissue replacements. The typical process of tissue
engineering starts with harvesting cells from a patient, typically through a biopsy (Figure
1.2). The cells are then expanded in vitro, and seeded onto scaffolds, which are materials
that support cells to grow on. The cellularized scaffolds are then cultured and allowed to
mature before implanting the construct back into the patient (4).

1.1 CONVENTIONAL TISSUE ENGINEERING TECHNIQUES
The conventional tissue engineering approach involves the creation of acellular
porous sacrificial scaffolds that are seeded with cells post-fabrication (5). The classical
tissue engineering approach involves the isolation and seeding of organ-specific cells or
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multipotent stem cells on different scaffold biomaterials (Figure 1.2; 6). Many
techniques have been employed, such as fiber bonding, solvent casting, and melt
molding, but proved to be minimally successful for tissue engineering applications. Fiber
bonding methods allow fibers to be aligned in specific shapes, but they are only capable
of producing very thin scaffolds (7). Solvent casting methods produced highly porous
constructs, however the largest produced membrane was only 3-mm thick (8). Therefore,
creating larger, organ-sized three-dimensional constructs is not feasible using these
techniques. Melt molding techniques proved successful in producing three-dimensional
scaffolds, but the high temperatures are required that biological materials cannot be
incorporated during the production process (7). Scaffolds seeded post-fabrication are
limited in their ability to meet the requirements of tissue engineering to produce threedimensional scaffolds with predefined or controllable microstructures and
macrostructures (9). Another major issue with solid scaffold seeding technologies is the
deficiency of vascularization and poor mechanical integrity (10-11).
1.2 BIOMATERIALS FOR SCAFFOLD-BASED TISSUE ENGINEERING
Biomaterials used to create the scaffolds for the development of cellular constructs
must satisfy multiple requirements. The scaffold serves as a temporary foundation for cell
attachment and proliferation, so it must be constructed from materials with sufficient
mechanical properties, a timed biodegradability to non-toxic products, and a controllable
porosity (10,12-15). Additionally, the scaffold materials should not be cytotoxic or create
an adverse response from the host. The materials must allow for a uniform cell
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distribution within the bioprinted constructs, so that encapsulated cells are able to
migrate, communicate, and form intercellular connections for tissue maturation.
1.3 ADVANCES IN BIOFABRICATION TECHNIQUES FOR ENGINEERING SOFT
TISSUES: THREE-DIMENSIONAL BIOPRINTING
Bioprinting has since been extended to three dimensions through the use of nontoxic,
biodegradable, thermo-reversible or chemically crosslinked hydrogels to overcome the
disadvantages of conventional methods (16,17).
Types of Three-dimensional Bioprinters
A few of the solid freeform fabrication techniques currently being employed are
laser-assisted bioprinting and inkjet printing. Laser-assisted bioprinting techniques use a
pulsed laser source, a target plate, and a receiving substrate to generate three-dimensional
scaffolds (Figure 1.3; 18). However, this technique is limited due to low throughput, low
cell viability, and can only produce limited arrangements of fabricated structures because
only photo-crosslinkable prepolymers can be used to form a crosslinked hydrogel
network (15,19). Inkjet printing was developed as a non-contact methodology that
reproduces digital image data on a substrate by depositing picoliter ink droplets (Figure
1.3; 20,21). However, inkjet printing does not produce a high-resolution construct, the
fabricated constructs experience rapid protein denaturation, and many of the cells are
lysed during the deposition process (22-23). Microextrusion bioprinters utilize syringe
printer heads that deposit bioink in a drop-by-drop or layer-by-layer build-up approach.
The biomaterials used as bioink for extrusion printing must be structurally stable or
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include an in situ crosslinking mechanism to generate three-dimensional tissue
constructs.

Direct and Indirect Bioprinting Techniques
Bioprinting technologies typically utilize two methods for fabricating cellular
constructs. Indirect bioprinting involves the deposition of an acellular scaffold, shown
here in blue, that is first created to determine the geometry of the desired construct
(Figure 1.4; 24). This acellular mold is subsequently seeded with cells (red) to have them
assemble in the set architectures. Once the construct has matured, the acellular blue
scaffold is sacrificed leaving a cell-only construct. Direct bioprinting involves the
deposition of cell-laden bioink in specific geometries to fabricate tissue constructs in
cellularized patterns.
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Norotte, C., et. al. investigated the possibility of creating bioprinted constructs
with embedded vascular patterns via indirect bioprinting (Figure 1.5A-E; 17). They
created the sacrificial scaffold using non-adherent agarose (purple rods), and were able to
create tubes with various dimensions. The smallest tube created was 900𝜇m in diameter
and had a wall thickness of 300𝜇m. The seeded cells (orange) fused into multicellular
spheroids within 5 and 7 days of culture to produce a tubular construct. This group was
able to develop tubular structures with varying diameters and wall thicknesses, indicating
an ability to tailor this technology to specific vascular constructs.
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The creation of tubular cell constructs is an exciting achievement, but there were
many deficiencies observed with these constructs. The time to create larger constructs
was very time consuming as fusion of spheroids can take up to a week and may result in
non-uniform tubular surfaces. Additionally, the formed constructs indicated positive for
apoptotic cells, likely due to the limited diffusion of oxygen and nutrients to these
constructs.
1.4 SCAFFOLD-FREE TISSUE ENGINEERING
Scaffold-free tissue engineering aims to produce physiologically-relevant threedimensional multicellular constructs without the use of a scaffold. These methods have
been developed as ways to avoid the issues associated with scaffold materials, such as
toxicity of by-products, uncontrolled mechanical properties, and others, as well as to
develop more physiologically-relevant constructs that rely on the mechanisms driving
tissue development in vivo.
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Generation of Multicellular Spheroids
The creation of multicellular spheroids relies on the use non-adherent molds, which
means that the cells are unable to interact with or adhere to the material used (Figure
1.7). Cells are expanded on cell culture dishes, and then harvested using enzymatic
digestion, typically trypsinization (Figure 1.7B). The suspended cells, shown in blue, are
then seeded into the non-adherent mold, and cultured. Cellular constructs are formed in
the dimensions of the non-adherent mold with time in culture.

During the culture period, the cells undergo the process of cellular self-assembly,
which relies on the inherent capability of cells to migrate and for intercellular
connections (25). Adherent cells depend on the formation of these intercellular as well as
cell-matrix connections for survival. When adherent cells are placed in an environment
that lacks a surface for adhesion, the cells will aggregate and undergo the process of selfassembly. During this process, suspended cells form three-dimensional multi-cellular
spheroids. The produced multicellular spheroids have similar architectural and functional
characteristics of native tissues.
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Cell Sheet Engineering
Another emerging technique for generating scaffold-free constructs, is cell sheet
engineering. Harvesting cells via enzymatic digestion, trypsinization, cell-cell junctional
proteins and deposited extracellular matrix are disrupted and degraded for cell recovery
(Figure 1.7B). To overcome this limitation Yang, J., et. al. developed temperatureresponsive cell culture dishes to create scaffold-free cellular sheets (26). The
temperature-responsive cell culture dish is created by covalently attaching a thermoresponsive polymer, poly(N-isopropylacrylamide) (PI-PAAm). During normal culture
conditions, 37℃ and 5% CO# , the surface is hydrophobic and allows cell attachment,
migration, and proliferation. Once a confluent monolayer has been established on the
culture plate, the temperature is reduced to 32℃, or the PI-PAAm lower critical solution
temperature, which causes the dish surface to become hydrophilic and swell (Figure
1.7C). A hydrated layer forms between the cells and the culture plate, which permits their
spontaneous detachment without the need for enzymatic digestion. This retains essential
cell surface proteins like ion channels, growth factor receptors, and cell-cell junctional
proteins within the cell sheet constructs. Additionally, the deposited extracellular matrix
is harvested with the cellular sheets, allowing for the reconstruction of multiple tissues
and organs using this technique.
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1.5 LIMITATIONS IN TISSUE ENGINEERING
The field of tissue engineering advances an exciting array of solutions for organ
repair and wound healing. However, to realize this potential, several hurdles must be
overcome. Vascularization is arguably the most important practical limitation in tissue
engineering, imposing both dimensional and time constraints on the technology.
Vascularization and fast anastomosis with the host are essential in engineering cellular
constructs that survive once implanted, as well as tissue maintenance and regeneration.
Endothelial cell migration and physiological growth of new blood vessels in vivo has
been reported to occur at ~5 um/hour due to the availability of oxygen, which is limited
to a diffusion distance of 150 − 200µm from a supplying blood vessel (27-28).
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With the clinical need being for larger engineered tissues, a major focus in the tissue
engineering field has been on designing constructs with pre-existing vascular
architectures (Figure 1.5) or, more recently, prevascularized constructs. This dissertation
focuses on the integration of scaffold-based and scaffold-free techniques to develop novel
technologies for engineered tissue replacements and wound dressings that address the
limitations described in this chapter.
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CHAPTER TWO
BIOFABRICATION AND BIOMATERIALS
Organ transplantation has been limited by two major factors: a critical shortage in
donors and a high risk of graft rejection (58). With over 120,000 patients on the organ
waiting list as of 2017, transplantation is not a feasible option for many of these people
(54). Tissue engineering utilizes the principles of biology and engineering to develop
functional substitutes that serve to maintain, restore, or enhance native tissues and organs
(1). The traditional tissue engineering techniques involve the creation of a solid, porous
scaffold that is seeded with cells post-fabrication. The scaffold is designed to try to
encourage cells to form the desired tissue by the incorporation of specific cell types,
growth factors, or other signaling molecules (55). However, these techniques have been
met with limited success due to the lack of organization and hierarchy within the
constructs that is typically seen in native tissues. Additionally, under these conditions the
cells are unable to grow in favored three-dimensional orientations, which is often
accompanied by loss of tissue-specific function (3-5).
The capability of generating three-dimensional biomimetic constructs on demand
would facilitate scientific and technological advances in tissue engineering as well as in
cell-based sensors, drug/toxicity screening, tissue or tumor models, and other areas (2).
This has led to the direct fabrication of scaffolds with a complex, anatomically correct
external geometry, and precise control over the internal geometry (9). Three-dimensional
bioprinting is a methodology used for generating three-dimensional constructs of various
sizes and shapes from a digital model using a layer-by-layer approach (34). The
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fabrication of three-dimensional biomimetic constructs plays an essential role in the
advancement of tissue engineering, and the bioprinting process restores the ability to
form three-dimensional constructs that are able to recapitulate the in vivo-like structure
and function of complex tissues.
2.1 ADVANCED ADDITIVE MANUFACTURING BIOPRINTING
As an additive manufacturing technique, three-dimensional bioprinting involves
the deposition of either cell-laden biomaterials, or acellular biomaterials that are seeded
post-fabrication (54). Extrusion bioprinters have been developed as an expansion of
inkjet printing in order to deposit more viscous materials with higher local cell densities
(54). The versatility of these machines permits the deposition of almost all types of
hydrogel pre-polymer solutions with varying ranges of viscosity and cell aggregates (53).
These bioprinters are also able to deposit concurrent lines of cell-laden materials as
opposed to independent droplets in traditional techniques.
The typical workflow of extrusion bioprinting of cell-laden materials is shown in
Figure 2.1, and involves the isolation and expansion of human cells in vitro, mixing these
cells into a printable material, and finally, depositing cell-laden scaffolds in a layer-bylayer fashion (53; Figure 2.1). In these systems cells, proteins, growth factors, and others
can be integrated into the matrix materials during the fabrication process and
concurrently deposited using computer-controlled actuators to generate three-dimensional
cell-laden scaffolds that closely mimic the microarchitecture of native tissue (12,28,45).
The produced scaffolds can be used as therapeutic devices themselves (i.e. implant the
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generated constructs), as a testing platform for drug screening and discovery, as well as
an in vitro model for disease (53).

Bioprinting typically utilizes two methods for creating three-dimensional
constructs: direct and indirect printing. Direct bioprinting techniques have cells, as well
as other factors (i.e. growth factors, peptides, etc.), loaded in a cytocompatible bioink that
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are deposited together to generate cellularized scaffolds. Constructs generated with this
technique rely on a fast gelation/crosslinking in order to sustain the stable structure (44;
Figure 2.2). Indirect printing methods generate an acellular negative structure that serves
as a scaffold for cell-seeding post-fabrication (44; Figure 2.2).

2.2 BIOMATERIALS FOR EXTRUSION-BASED, DIRECT-WRITE BIOPRINTING
Human tissue biology is heavily regulated by specific interactions and cross-talk
between different resident cell populations. The three-dimensional organization of tissueengineered constructs is a fundamental component of the fabrication method because the
produced constructs must closely mimic the highly organized interaction of cells and
extracellular matrix in native tissue. The materials in which the cells are embedded
directly influences the mechanical and biological properties of the produced scaffold, as
well as subsequent cell behaviors within that scaffold. Therefore, the two most critical
factors for bioprinting functional tissue replacements are the biomaterials used to create

16

scaffolds and the cell types incorporated within those scaffolds in order to adequately
recapitulate these complex microenvironments in vitro (53,54).
Each technique for bioprinting has different requirements for the materials used to
create scaffolds, as discussed in chapter 1. Bioinks are typically comprised of cell-laden
pre-polymer solutions (53). The ideal bioink must satisfy specific material and biological
requirements because it serves as a temporary foundation of cell attachment and
proliferation. Important material properties include tunable mechanical properties,
printability, crosslinking mechanism, biocompatibility, and controlled degradation into
non-toxic by-products (4,6-9,47).
Extrusion-based bioprinters used for printing cell-laden materials are able to
incorporate higher cell densities than other techniques, and are able to print materials
with viscosities ranging from 30 − 60 × 10$ mPa (54). Cell-laden bioprinting requires
the material used for encapsulation has a high-water content and adequate porosity for
cells to receive nutrients and oxygen from the environment, and remove waste to sustain
viability within the scaffold (54). Hydrogels, both natural and synthetic, have been
frequently employed in bioprinting due to their structural similarity to the
macromolecular-based components of the body, and their tissue-mimetic properties (52).
These hydrophilic materials are able to absorb large amounts of water within their threedimensional networks, and retain this water in their swollen state (56).
The mechanical properties of hydrogels are significantly important for tissue
engineering applications where the gel must create and maintain a space for cell
infiltration and tissue development (52). The mechanical properties of the scaffolds post-
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polymerization must be adequate to sustain a suitable environment for cell attachment,
proliferation, and differentiation (53). These properties include shear stress, strain,
compressive modulus, and the mass swelling ratio (7).
Printability refers to the interaction between the deposited bioink and the printing
substrate that allows for the formation of high-quality, geometrically accurate constructs.
This property is related to the surface tension between the bioink and substrate, which
can be measured by the contact angles between the two materials, as well as the
resolution of the bioprinter (53). The deposited pre-polymeric bioink solution should
have a large contact angle with the substrate, which is produced when the bioink solution
maintains tension in the vertical direction (53). Bioprinters in the literature have reported
resolutions ranging from 10 − 10,000𝜇m (54). The wide range of resolutions is due to
the fact that many labs are developing novel in-house bioprinter setups for applications
that have specific requirements within this range. In general, bioprinters have a resolution
on the micron-scale, which is relevant on a cellular level (54). The crosslinking
mechanism of the bioink also has a large effect on its printability. In order to deposit cellladen solutions, the materials must be polymerized post-printing. Therefore, the
mechanism for gelation must be gentle on cells and not impact cell viability. There are
three dominant methods of crosslinking frequently used for bioprinting applications: 1)
photo-crosslinking, 2) physical crosslinking, and 3) chemical crosslinking (53). Photocrosslinking utilizes the polymerization of light-sensitive polymers, however, many of
these techniques require the use of ultraviolet (UV) light, which can be toxic to
encapsulated cells, as well as degrade the matrix in which the cells are embedded (54).
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Chemical crosslinking leads to the formation of permanent junctions, while
transient/reversible three-dimensional polymer networks are formed via physical
crosslinking, such as thermal crosslinking techniques (56).
Biocompatibility is determined by how the biomaterial performs with the host
response in a specific situation. In vitro, it is required that the material is not harmful to
cell survival, proliferation, and provides proper binding sites for cells embedded within it
(53). In vivo, it is additionally required that the biomaterial can be degraded or
incorporated into the native extracellular matrix without producing toxic by-products or
resulting in destructive interactions with host cells (53). Once implanted, biodegradable
hydrogels can be broken down into lower-molecular weight, water-soluble fragments that
can be resorbed or excreted by the body once the function of the gel has been completed
(52). This makes these materials promising choices for releasing drugs or other factors in
a clinically-relevant timeline.
2.3 MODIFIED ALGINATE AS A BIOACTIVE SCAFFOLD
More recently, the engineering of “smart”, or bio-functional, and composite
materials have evolved due to the limitations of using a single material for various
bioprinting applications (53). Native alginate, which is arguably the most frequently used
bioink in bioprinting applications due to its biocompatibility and gentle gelation
mechanism (30,59). Alginate is a natural polysaccharide derived from seaweed, and is
comprised of alternating chains of polyguluronate (G) and polymannuronate (M) (Figure
2., 60). The mechanical properties, pore size, and crosslinking density of the alginate
polymers can be controlled by varying the M:G monomers ratio (60). It has been shown
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that alginates containing a high fraction of polyguluronate blocks produces gels with
superior strength compared to those with high amounts of polymannuronate (60).
Alginate is polymerized in the presence of divalent cations, like calcium, that ionically
crosslink the carboxylate groups in the polyguluronate blocks of the copolymer structure
(30,60). However this material is bioinert, i.e. lacks cell-binding sites, contains minimal
cell-activating properties, and only gets minimally degraded in vivo (54). The in vivo
degradation of native alginate is caused by the loss of divalent cations in an uncontrolled
manner, and results in the release of both low- and high-molecular weight strands. The
resultant high-molecular weight strands are not easily broken down and may take long
periods of time to be cleared from the body, if at all.

To expand on this material for regenerative applications, alginates functionalized
with RGD-binding sites have been frequently used as bioink to provide a matrix scaffold
that will direct a specific 3D cell growth (37). Scaffolds made using RGD-conjugated
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alginate were shown to be capable of forming robust cell-compatible hydrogels in
physiological conditions (7,14,17,44).

Additionally, chemically modifying the alginate through oxidation has been
demonstrated in the literature to produce scaffolds with controllable degradation rates
(37). Partial oxidation using sodium periodate alters the conformation of the uronate
residues into an open-chain adduct, which are vulnerable to hydrolysis (Figure 2.5, 61).
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By changing the polymeric chain to an “open” state the pore size of the resultant
hydrogel is less dense as well as the stiffness, which has been reported to enhance cell
viability in implanted constructs (37, 61). For example, Jia, et. al. showed that varying the
degree of oxidation and concentration of the alginate used effected the viability human
Adipose-derived stem cells in bioprinted constructs (Figure 2.3; 37). High viabilities
(>90%) were associated with alginate bioinks with medium viscosities (~400mm# s %& ),
while low viabilities were observed in high viscosity bioinks (~3,000mm# s%& ). The
differences seen in cell viability between the materials was attributed to the denser
polymeric environment associated with high viscosity alginates, which diminished
nutrient transport to the cells embedded in these constructs (37). Therefore, when using
modified alginate as a vehicle for cell encapsulation and transplantation, it is essential to
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determine the appropriate environment required for the specific application and to modify
the materials to meet those demands.

Another avenue for material modification is the combination of multiple materials
to produce a heterogeneous scaffold. Through the combination of different hydrogels, the
synthesized scaffold’s properties are modifiable to meet distinct application requirements.
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To further expand alginate as a useful material for regenerative tissue engineering
applications it could be combined with collagen to provide structural and cell-adhesive
properties. Collagen is the most abundant protein in mammalian tissues and is the main
component of natural extracellular matrix (46). It inherently contains RGD cell-binding
sites, and provides structural support and mechanical strength to tissues in vivo (46,57).
Additionally, collagen is known to permit cell adhesion, chemotaxis, and migration,
making it a good candidate for bioprinting applications. We have developed
collagen/alginate blend hydrogels that, in collaboration with other labs at the Medical
University of South Carolina, have been explored for applications including timed drug
release of vancomycin for surgical implant sites (provisional patent submitted), as well as
for the attachment, migration, and subsequent release of regulatory T-cells for in vivo
applications (provisional patent submitted). The incorporation of additional materials or
chemical modifications could expand the use of this material to a multitude of different
applications, such as wound healing and fabricating soft tissue replacements.
2.4 MIMICKING THE COMPLEX IN VIVO MICROENVIRONMENT
Every tissue in the body is composed of multiple cells types positioned relative to
each other in specific, complex orientations and patterns. To replicate this on a cellular
level in vitro, the hydrogels that constitute the bioink can be heterogeneous, i.e.
consisting of multiple cell types and/or materials, or homogeneous, depending on the
tissue being replicated. Additive manufacturing systems deposit these multicellular
building blocks, or the bioink, drop-by-drop or layer-by-layer via disposable syringes and
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tips onto a computer-controlled stage capable of moving in the x, y, and z directions.
Through computer software, the architecture of printed scaffolds can be easily
manipulated to mimic tissue-specific patterns depending on the requirements of the
application. Unlike conventional techniques, three-dimensional medical technologies (i.e.
magnetic resonance imaging, computer tomography) can be incorporated into the
designs, which enables the possibility of generating patient-specific constructs (10).
2.5 THE PALMETTO BIOPRINTER
The Palmetto Printer is a custom built three-dimensional multi-dispenser system
that uses programmable robotic manufacturing methods to generate three-dimensional
heterogeneous tissue constructs (Figure 2.4). It allows the use of a plurality of materials
in unique combinations to produce heterogeneous structures. The initialization of the
bioprinter is one of the most important steps in bioprinting because it allows you to set a
variety of parameters to optimize the printability of the bioprinted constructs.
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The bioprinter comprises a batch type process with startup, operation and
shutdown sequences controlled by a programmable logic controller (PLC), which the user
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operates through an interactive touch screen control panel (Figure 2.4, A). To prevent
contamination of biological materials the bioprinter is enclosed in a positively-pressured
poly(methyl methacrylate) (PMMA) chamber with a high-efficiency particulate
arrestance (HEPA)-filtered air circulation system (Figure 2.4, B,C). The interior of the
printer can be sterilized using the built-in ultraviolet light sources (Figure 2.4, D). The
central component of the bioprinter is a fully programmable positioning robot that can
reproducibly place a dispenser tip with an accuracy of 10 micrometers (Figure 2.4, E).
There are three dispensers, which are able to deposit volumes as small as 230 nanoliters
using a rotary screw (Figure 2.4, F). They are independently programmable using
separate computers that govern printing parameters for each dispenser (Figure 2.4, G).
Rotary-screw dispensing utilizes the rotation of a motor-driven screw to move bioink
down a syringe and out of the syringe tip. These dispensers are mounted onto a
pneumatically controlled Tool Nest (Figure 2.5, A, B), allowing the robot to switch
dispenser mounted onto the Z-axis robotic arm under programmed control (Figure 2.4,
H).
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The XYZ robot receives printing instructions from a computer running design
software (Figure 2.4, I). Each program contains dispensing locations, calibration
routines, and dispenser-changing protocols. The design of generated constructs primarily
consists of the XYZ coordinates where each dispenser will deposit material. The
bioprinter comprises two optical light sensors (Figure 2.5, C) that determine the XYZ
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coordinates of the syringe tip end. These sensors send coordinate information to the
robot, which uses these to calculate positions of the dispenser tip ends. There is an
additional displacement laser (Figure 2.4, D) that projects a 633 nm diode red laser beam
of spot size 30 x 100 micrometers to measure distance with an accuracy of 0.1
micrometers. When the beam is highly focused the robot determines the Z distance of the
printing surface. This measurement, and the optical light sensors measurement of the tip
end in Z, allows calculation of accurate Z coordinates used to place the dispenser tip in
relation to the printing surface. The dispenser tips move laterally and vertically through
the X-axis oriented optical light sensor to find the Y and Z centers, and laterally through
a Y-axis sensor to find the center of the X-axis. The printing surface is mapped using the
formula for a flat plane in xyz space: ax + by +cz = d to determine where the surface is
relative to the position of the dispensing tip end. The printer stage (Figure 2.4, J) holds a
sample Petri dish up to 80 mm in diameter and uses a recirculating water bath to maintain
the set temperature (Figure 2.4, K). Stage temperature can be set within a range of -20
and remains stable within a range of -20-100 degrees Celsius and remains stable within
0.5 degrees Celsius. There is a USB camera mounted onto the robot Z-arm to provide a
magnified view of the dispensing tip during the printing process (Figure 2.4, L). There is
a second camera mounted towards the top of the chamber interior that provides a
complete view of the bioprinter during the printing process (Figure 2.4, L).
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A computer-aided design drawing software determines the deposition pattern and
permits the user to generate incrementally spaced droplets and complex structures
(Figure 2.6). Three- dimensional pathways can be manually coded into the printercompatible design software or imported from a separate computer-aided design drawing
software (Figure 2.7, Table 2.1). The printer-compatible software allows variations of
printing parameters such as the deposition method (single droplet deposition or
continuous pathway deposition), three-dimensional geometry of the pathways, deposition

31

rate, distance between the syringe tip end and substrate printing surface, the amount of
time to deposit an individual drop, and the height and speed the syringe is lifted between
deposition of the drops. Each program contains XYZ dispensing locations, tip calibration
routines, and dispenser-changing protocols to provide a sterile environment, without
operator intervention, during printing. The programmable logic controller (PLC) of the
robot receives instructions from the computer running the design software and controls
the timing of events from the external controllers (e.g. the dispensers). To do this, the
PLC uses a looping mechanism to control the dispensers, robotic positioning device, and
environmental factors.
In this study we aimed to characterize a variety of materials that could function as
vehicles for the transplantation of cell-laden constructs by analyzing different material
properties and cell behaviors within these biomaterials. We hypothesize that the Palmetto
Printer, developed at MUSC, is capable of depositing viable cell-laden structures in
biomimetic geometries that accurately replicate the in vivo environment with respect to
mechanical properties and cellular functions.
2.6 MATERIALS AND METHODS
Collagen Extraction
Collagen was extracted from the hide of an 18-month-old bovine steer following the
methods of Yost, et al. (50). The superficial epidermis, including the hair and follicle pits,
was first removed using a scalpel. The hide was then cut into 4 × 6 cm strips and was
washed three times in deionized water for 1 hour per wash, with the second wash
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including 0.2% NaHC)' . The leftover follicles and non-collagenous proteins were
removed by washing in a solution of 0.6% NaHCO' , 2% Ca(OH)# , and 4.3% NaHS for
30 minutes at 20℃. The hides were then washed three times in deionized water and
soaked in 2% Ca(OH)# at 4℃ overnight. The fat and epidermis remaining after the
overnight wash was trimmed, and the strips were placed in a 2M sodium chloride (NaCl)
solution and neutralized with hydrochloric acid (HCl) to pH 6.8-7.0. The hide strips were
then washed three times in deionized water, and cut into smaller 0.5 × 2 cm pieces and
placed into a solution of 0.5Nacetic acid, containing pepsin (1:100 based on hide weight),
and incubated overnight at 4℃. The strips were then mixed with ice and emulsified into a
gel dispersion using a Kitchen-Aid food processor (model FP500WH; Kitchen-Aid, St.
Joseph, MD). The suspension was centrifuged at 9950 × g for 35 minutes, resuspended
in deionized water, and neutralized to pH 7.2 with NaOH. The collagen suspension was
then dialyzed versus phosphate-buffered saline overnight, and then versus deionized
water for three changes over 24 hours. The resulting collagen gel was centrifuged at
9950 × g for 35 minutes to remove excess water, and the collagen concentration was
adjusted to 25

mg
CmL by adding deionized water. The collagen was then aliquoted into

50mL tubes and stored at −20℃ until ready for use.
Synthesis of Collagen Bioinks
When ready for use, the collagen was thawed, diluted to the appropriate concentration
using deionized water, and the pH was adjusted to pH 2.5-3.0 with concentrated HCl.
Once acidified, the collagen was diluted to the desired concentration using cold, 4℃,
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deionized water. The pH was then checked again, and if it was not pH ~3.0, the collagen
was again acidified using concentrated HCl.
Synthesis of Alginate Bioinks
Sodium Alginates, Protanal LF 20/40 and Protanal LF 10/60 FT, were generously
provided by FMC BioPolymer (Philadelphia, PA). The alginate powder was sterilized via
gamma irradiation (at 1200cGy for X minutes) followed by UV exposure for two hours in
a cell culture hood. To make 50 mL of 5% (weight-to-total volume) alginate bioink, 2.5
grams of sodium alginate was mixed with 50 mL sterile ddH# O. It was then kept in the
cell culture hood until use.
Oxidation of Alginate Hydrogels
Sodium alginate was oxidized following the method for partially oxidized alginate by
Bouhadir, et. al. (30). To make a 5% oxidized alginate solution 1 gram of sodium alginate
was dissolved in 100mL of distilled water. An aqueous solution of sodium periodate
(0.25M, 0.25 mmol), the oxidizing reagent, was added to produce a 5% oxidation
solution. The solution was stirred for 19 hours at room temperature. Finally, at the 24
hour time point, 40 mL of ethylene glycol was added to the solution to end the reaction.
2.5 grams of sodium chloride was added to the solution, as well as an excess amount of
ethyl alcohol (2:1) in order to precipitate the oxidized alginate. The solution was
centrifuged at 1000xg to collect the precipitates, which were then re-dissolved in distilled
water. The ethanol wash was then repeated. The pellets were freeze-dried and stored at
−20℃ until ready for use. The degree of oxidation was determined by measuring the
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percentage of sodium periodate consumed before being terminated by the ethylene
glycol. This was accomplished by preparing a potassium iodide solution (20% w/v, pH
7.0 sodium phosphate buffer) and a thyodene solution (10% w/v, pH 7.0 sodium
phosphate buffer). The two solutions were mixed with the oxidized alginate at room
temperature. The reacted alginate and sodium periodate solution were gradually dropped
into the mixed potassium iodide and thyodene solutions. The absorbance of the mixture
was measured spectrophotometrically at 426nm. When the maximum absorbance was
reached, the used volume of the alginate and sodium periodate solution was recorded as
%
%
V& . The reaction is IO%
( + 2I = I# + IO' , and the amount of unreacted sodium periodate
)

!+

was calculated using the following formula: 20% I * J × 10mL × 100 , . The amount of
!

unreacted sodium periodate was subtracted from the original concentration to determine
the amount of sodium periodate consumed during the reaction and the degree of
oxidation of the alginate.
RGD-conjugation onto Alginate Hydrogels
Ligands with an exposed arginine-glycine-aspartate sequence (G( RGDSP peptide) were
conjugated onto the previously oxidized alginate by following the RGD-Alginate
conjugation method described by Rowley, et. al. in order to promote cell attachment and
spreading (31). Aqueous carbodiimide chemistry with G( RGDSP was used to conjugate
the RGD peptide onto the alginate polymer. 1 g of 5% oxidized alginate was dissolved in
a 0.1 M 2-(N-morpholino) ethanesulfonic acid (MES) buffer, pH = 4. 1-ethyl(dimethylaminopropyl) carbodiimide (EDC, 0.54 mmol) and N-Hydroxysuccinimide
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(NHS, 0.27 mmol) were added at 2:1 ratio to form amide intermediate. 0.28 mmol
G( RGDSP peptide was added, which couples to the backbone of the alginate polymer via
the terminal amine, and stirred overnight. The coupling reaction was terminated by
adding 2.5 g sodium chloride to the solution. An excess amount of ethyl alcohol (2:1)
was added to precipitate the RGD-conjugated oxidized alginate. The mixture was
centrifuged at 4,000xg for five minutes to collect the precipitates. The supernatant was
aspirated in the cell culture hood, and the precipitates were re-dissolved in distilled water.
The ethanol wash was then repeated. The samples were then freeze-dried and stored at
−20℃ for later use.
RGD Peptide Conjugation Analysis
The success of RGD peptide conjugation on the alginate was determined by comparing
RGD-alginate and non-conjugated alginate. This was done by imaging the printed
constructs using (4’, 6-Diamidino-2-Phenylindole, Dihydrochloride) (DAPI) and
phalloidin stains. The phalloidin working solution was created by diluting 5𝜇L of the
methanolic stock solution with 200𝜇L of DPBS++. A 300𝜇M stock solution of the DAPI
stain was made following the equation:

1
-.&-/-0 2+
1
'/-.' 2!34

= 3 × 10%( M = 0.0003M =

0.300mM = 300µM. The DAPI working solution was made by diluting the stock
solution 1:100 in DPBS++ to obtain 3𝜇M solution. The samples were completely
submerged in 37℃, 4% paraformaldehyde, and incubated for one hour at room
temperature. The samples were then washed three times with DPBS++, and the solution
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was allowed to sit for 5 minutes each wash. The gel samples were then transferred from
the well to a glass slide, and the gel was flipped over in the process. The samples were
-.&1

then immersed in 0.1% Triton X-100 (&--!+) in DPBS++ for ten minutes. Each sample
was washed three times in DPBS++ for five minutes per wash. The bioprinted constructs
were stained with phalloidin by immersing them in the working solution in the dark for
four hours. The phalloidin stain was removed and the samples were washed three times.
The first wash was fast (~45 seconds), while the latter washes were for 5 minutes each.
The bioprinted constructs were stained with DAPI by immersing them in the DAPI
working solution in the dark for thirty minutes. The samples were washed three times for
5 minutes per wash. The samples were imaged on a confocal microscope system and
analyzed.
Preparation of 𝑪𝒂𝟐6 -Contatining Gelatin Substrate for 3-D bioprinting of Alginate
Hydrogels
The calcium substrate was prepared following the methods by Pataky et al in order to
avoid reduced viability associated with high concentrations of Ca#6 (11). Briefly,
calcium chloride dehydrate, sodium chloride (0.9 wt.%), and porcine gelatin (2 wt.%)
were combined in distilled water and boiled for 2 minutes to form a 100mM CaCl#
gelatin solution. To increase the opacity of the surface, titanium dioxide (0.3 wt.%) was
added to the gelatin solution and stirred for 10 minutes. 5 ml of gelatin/TiO# mixture was
put into standard petri dishes and left to gel in the 4℃ refrigerator overnight to be used
within 3 days.
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Cell Culture
Human adipose tissue stromal cells (hADSC’s) were cultured in 75 cm treated cell
culture flasks (T75 flasks), covered with 15 mL low glucose DMEM with 10% fetal
bovine serum and 1% penicillin-streptomycin, 1% glutamine, and 1% antimycin. Media
was changed every two days until the cells reached confluence (80-90%). Once
confluent, the cells were suspended via trypsin enzyme digestion method.
Normal Human Dermal Fibroblasts (NHDF) were cultured in 175-cm treated cell culture
flasks (T175), covered with 25 mL of Fibroblast Growth Medium-2 (FGM-2, Lonza).
The media was changed every two days until the cells reached ~85% confluence. Once
confluent, the cells were suspending using trypsin enzyme digestion.
Human Adipose Microvascular Endothelial Cells (HAMEC) were cultured in 75 cm
treated cell culture flasks covered with 15 mL of Endothelial Growth Medium-2 (EGM-2,
Lonza). Media was changed every two days until the cells reached 80% confluence. Once
confluent, cells were suspended via trypsin enzyme digestion method.
Bioprinter Setup
First, the bioprinter was turned on, as well as each of the dispenser computers and the
recirculating water bath. The recirculating water bath temperature was set to 4℃ in order
to maintain the gelatin substrate solution in a solid state. The printing parameters were
manually set for each dispenser on the correlating dispenser computer, including the
dispense volume, back-off steps, and the dispense rate. The JR-C points design software
was opened, and additional printing parameters were set, including the distance between
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the tip end and the substrate surface, the distance the syringe is lifted between
depositions, and the amount of time per deposition. The program was saved and then sent
to the robot. The gelatin/TiO# -containing Petri dish was placed on the 4℃ printer stage,
and the chamber door was closed and locked. The PLC was used to initialize the
ultraviolet light sources for 90 seconds in order to sterilize the chamber. Once the
sterilization was complete, the chamber door was briefly opened, and the syringes are
loaded into their appropriate gun location. The PLC was then used to turn on the fan
system, which takes 30 seconds to reach equilibrium internal pressure within the
chamber. Finally, on the computer the appropriate program containing the geometrical
pathway and printing parameters was run.
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Contact Angles of Bioprinted Droplets
Contact angle measurements were taken to determine the printability of different
materials and analyze the surface interactions during deposition. Assuming compatible
surface adhesion properties, the contact angle should be high. It is valuable to predict the
droplet dimension at different system configurations and process conditions for planning
the printing sequences (49). The contact angle measurements were calculated using the
formula in Figure 2.8.
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A 20G Micron-S tip with 0.00023cc, 0.00045cc, and 0.00135cc deposition volumes, 0
back-off steps, 0.25mm tip height was used for all experiments. Contact angle
measurements for 30% Pluronic F-127, 5% Protanal LF 10/60 FT, 5% Protanal LF 20/40
were compared (n=10).
Volume Analysis of Bioprinted Droplets
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To determine the actual volume deposited by the bioprinter for different set dispense
volumes, bioprinted droplets were measured in CellSens. The droplets were irregular in
shape, so they were divided into two sections to accurately calculate the dispensed
volume (Figure 2.9). The top half of the droplets were hemispherical in shape, and the
#

volume for this portion of the drop, V& , was calculated as V& = ' 𝜋r ' . The bottom half of
the drops, V# , were cylindrical in shape, and the volume was calculated as V# =
(8! 68" )×;×<#
(

. The total volume for each drop was found by summing the two volumes,

Total Volume = V& + V# .

Resolution of the Palmetto Bioprinter
To determine the accuracy and reproducibility of the Palmetto bioprinter, droplets were
sequentially deposited on top of a previously deposited droplet and the offsets were
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measured. Using a 30G Micron-S Precision tip, the green droplets are deposited first with
a dispense volume of 0.00135cc. The red droplets were deposited after gelation of the
first droplets at a dispense volume of 0.00023cc, so the offsets from the center of the
droplets can be quantified. Offsets were calculated as: Offsets = Green(X,Y)-Red(X,Y).
Swelling Characteristics of Alginate Hydrogels
Hydrogels are composed of hydrophilic polymer networks that are biodegradable and
contain pores and void space between the polymer chains, which act to provide an
enhanced supply of nutrients and oxygen to the cells contained within them. To
characterize the polymer volume fraction in the swollen state, i.e. the amount of water
that can be imbibed by the hydrogel, the swelling properties of alginate hydrogels were
analyzed. Two experiments were performed to determine swelling properties of alginate
hydrogels.
The first experiment was designed to determine if the concentration of alginate, as well as
its molecular weight, have an effect on the swelling properties of the hydrogels. This
portion of the experiment includes the comparison of 2% and 4% LF20/40 alginate
bioinks, as well as 4% LF20/40 and 4% LF10/60FT. LF20/40 is a high molecular-weight
alginate, while LF10/60FT has a low molecular-weight, indicating the chain densities
between these two polymers are different, and therefore, may have different effects on
the materials printability and cell viability within it (54).
To determine the effect of the concentration, and therefore availability, of the gelation
agent, Ca#6 , three different solutions were used in the substrates to form alginate
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hydrogels: (1) 200 mM, (2) 300 mM, and (3) 400 mM CaCl2. Each gelation solution also
included 0.9%(w/v) NaCl dissolved in deionized water. Gels were created in 12-well
plates, with 0.5mL of calcium solution deposited on the bottom, followed by ~2.8mL of
alginate.
The alginate hydrogels were created by plating 0.5mL of 300mM CaCl# and 0.9% NaCl
in deionized water at the bottom of each well of a 12-well plate. Approximately 3mL of
alginate hydrogel was then added to each well and allowed to gel overnight at room
temperature. The next day, the gels were weighed for initial wet weights, and transferred
to wells in a 6-well plate with 8mL of PBS (made from tablet) in each well, and placed in
the incubator at 37℃. The gels were pulled out of the incubator on days 1, 2, 5, 6, and 7
for weight analyses. On day 7, the swollen (wet) gels were weighed, then the gels were
dried to determine the air-dried weight for each sample.
The swelling properties of hydrogels include the swelling ratio, Q, the mass loss
percentage, the equilibrium mass swelling ratio, Q ! , and the water uptake content, Q ) .
The swelling ratio, Q, is defined as the fractional increase in the weight of the hydrogel
!#$

due to water absorption, and is calculated by Q =

!%&

, where m"= is the mass of the

hydrogel at time T, and m)& is the mass of the hydrogel at time 0. The equilibrium mass
swelling ratio, Q ! , is the mass of the hydrogel immediately post-fabrication compared to
the mass of air-dried and calculated as Q ! =
Finally, the water uptake content, Q ) =

!#$
"'

!#$ %"'
"'
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, where W> is the air-dried weight.

× 100%.

Cell Distribution Within Bioprinted Droplets
A homogeneous cell distribution within bioprinted droplets is crucial for cell
communication, proliferation, and interconnectivity. High local cell densities are required
for successful cell differentiation and generation of extracellular matrix. To date,
achieving a uniform distribution of cells within bioprinted droplets has been a challenge
in bioprinting. Current technologies typically have an aggregation of cells towards the
innermost region of the droplet, which can inhibit cell-cell communication and
subsequent activities, such as migration. To demonstrate the Palmetto Printer is unique in
its ability to produce three-dimensional scaffolds with uniform cell distributions
throughout, multiple cell types and materials were analyzed post-printing.
A 0.62% Collagen and 4% LF 20/40 (1:1) blend bioink was seeded with Human Adipose
Microvascular Endothelial Cells (HAMEC) and Normal Human Dermal Fibroblasts
(NHDF) at a 1:4 ratio with a cell density of 1,000,000 cells/mL (n=5). A 5% LF 20/40,
high molecular-weight alginate, was seeded with NHDF only at 1,000,000 cells/mL
(n=9). Additionally, 5% LF 10/60 FT, low molecular-weight alginate, was seeded with
HAMECs at 1,000,000 cells/mL (n=7).
The bioink was then loaded into printer syringes, transported to the printer, and printed in
a 5 x 2 dot array onto a gelatin/TiO# substrate. The following printing parameters were
used: deposition volume of 0.00045 ml, deposition rate of 0.010

!+
?

, tip height of 0.1

mm, 10 backsteps, stage temperature of 4℃, a height of 15 mm the syringe was lifted
between depositions, and a 22-gauge plastic tip (Fishman). The constructs were allowed
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to gel for 40 minutes. While the constructs were gelling, a fluorescent-based stain
(Invitrogen Life Technologies) was made following the protocol of the kit. The cellladen hydrogels were then immersed in the stain for 15 minutes, in the dark, prior to
imaging. All of the fluorescent images were taken on a Leica TCS SP2 AOBS confocal
microscope system using Z-stack parameters of 103 optical slices over a 326.40µm
depth. Pictures of each droplet were taken individually. These images were then imported
into CellSens software and each was sectioned into quadrants and concentric circles.
Cells were manually counted for the entire droplets and each section within the droplets.
Cell Viability in Bioprinted Constructs
To quantify the viability of the constructs, stain them using a fluorescent-based
viability/cytotoxicity assay, and image using confocal microscopy. Following the kit
instructions, prepare a staining solution containing calcein AM and ethidium homodimer1. To make 10 mL of staining solution, add 20 microliters of the ethidium homodimer-1
and 5 microliters of the calcein am to 10 mL of sterile, tissue culture-grade Dulbecco’s
Phosphate-Buffered Saline (+magnesium, +calcium; DPBS++). Image the stained
constructs using a confocal microscope system at days 0 and 8. Take multiple pictures of
each bioprinted construct, using Z-stack parameters of 30 optical slices over a 300𝜇m
depth, and manually count the cells. If cells appear yellow or green they are counted as
alive, and if red, they are counted as dead.
Cell viability was calculated using the following formula:

46

Viability =

# 4B*C DC44? (1ECCF6GC443))
# H3HI4 DC44? (1ECCF6GC443)6EC>)

× 100%.

Cell Proliferation in Bioprinted Constructs
To quantify the amount of cell proliferation within the bioprinted constructs, they were
stained with a fluorescent-based viability/cytotoxicity assay on day 0 and 8, and imaged
using confocal microscopy. Multiple pictures were taken of each bioprinted construct
with Z-stack parameters of 30 optical slices over a 300𝜇m depth, and the cells were
manually counted. The amount of cell proliferation in bioprinted constructs over 8 days
was calculated using the following equation:

Proliferation =

# 4B*C DC44 D3JFH 3F >IG K
# 4B*C DC44 D3JFH 3F >IG -

× 100%.

2.7 RESULTS
RGD Peptide Conjugation Analysis
To analyze the success of RGD peptide conjugation on the alginate bioink, a comparison
experiment was performed using cell-laden, RGD-conjugated 15% concentration, 5%
oxidation alginate bioink and cell-laden, non-conjugated 15% concentration, 5%
oxidation alginate bioink. DAPI staining for nuclei and phalloidin staining for actin were
used to analyze the cell spreading in printed constructs on day 8. Images of each sample
(at least three random pictures per sample) were taking using a confocal microscope
system using Z-stack parameters of 30 optical slices over a 300𝜇m depth (Figure 2.14
A,B).
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The cell spreading shown in the sample with RGD-conjugated alginate proves the
successful incorporation of the peptide on the alginate. Additionally, Jia, et. al., who we
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worked in collaboration with for this project, previously demonstrated that the cell
adhesive and migratory properties were not limited to certain regions of the construct, but
occurred throughout (Figure 2.14C, 37). Cell migration is an important step in tissue
development, therefore the conjugation of RGD peptides on alginate improves the
likelihood of in vivo application using this bioink.
Contact Angles of Bioprinted Droplets
A 20G Micron-S tip with 0.00023cc, 0.00045cc, and 0.00135cc deposition volumes, 0
back-off steps, 0.25mm tip height was used for all experiments. Contact angle
measurements for 30% Pluronic F-127, 5% Protanal LF 10/60 FT, 5% Protanal LF 20/40
were compared (n=10; Figure 2.15).
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For the smaller dispense volumes, 230 nL and 450 nL, there were significant differences
between the materials tested. However, all of the materials tested had appropriate contact
angles (> 90°), indicative of maintained tension in the vertical direction, a requirement
for the printability of these materials. Therefore, all three of these biomaterials could
serve as vehicles for the construction of cell-laden constructs based on this requirement.
Volume Analysis of Bioprinted Droplets
Dispense volumes for acellular 5% LF20/40 alginate were measured using CellSens
(n=10). A dispense volume of 0.00135cc with a 0.30mm tip height and 0 back-off steps
was used to compare the volumes dispensed when using a 27G versus 30G Micron-S
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Precision Tip. The two tips were shown to deposit significantly different volumes
(P<0.006), which highlights the decreasing volume with increase of tip gauge size, i.e.
decreased diameter with increasing gauge size of the tip (Figure 2.16). This suggests that
the volume of deposited droplets is dependent on gauge size, and that due to the increased
surface tension in the smaller diameter tips they dispense a smaller volume than the larger
diameter tips.

Resolution of the Palmetto Bioprinter
The resolution of the Palmetto Printer was found to be 10 nanometers (Figure 2.17). The
results demonstrate the bioprinter is capable of depositing cell-laden hydrogels in specific
three-dimensional locations accurately and consistently using computer-aided software.
The software determines the placement of each droplet and controls many of the
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parameters for dispensing (Figure 2.5). The repeatability of the bioprinter to
appropriately deposit biomaterials is fundamental to its success in tissue engineering
applications.

Swelling Characteristics of Alginate Hydrogels
The day 1 swelling ratio, Q, was analyzed because that was the time point at which the
most mass increase was observed in all hydrogels compared to any other time in culture
over 7 days.
Independent t tests were used to compare 2% LF20/40 and 4% LF20/40 over 7 days
(n=8), and determine the impact of alginate concentration, i.e. polymer density, on the
swelling properties of the hydrogels (Figure 2.18). The day 7 swelling ratio, Q, between
the two group was not different (P<0.461). Additionally, the water uptake content, Q ) ,
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for the two hydrogels was not different (P<0.336). There were no significant differences
between these two groups, which suggests that the concentration of the alginate has
minimal effect on the materials’ water absorption properties.
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LF 20/40 is a high molecular weight alginate, and LF 10/60FT is a low molecular weight.
To determine the effect of polymer network density, the two materials were compared
(Figure 2.19).

The second half of this experiment aimed to discern whether the availability of the
gelation agent, in this case Ca#6 , in the substrate has an effect on the swelling properties
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of alginate hydrogels. 4% LF10/60FT gels made with three different concentrations of
calcium in the substrate were compared in Figure 2.20. Interestingly, there were no
significant differences between any of the groups for the varying concentrations of Ca#6 .
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2% LF20/40 alginate hydrogels created in varying concentrations of calcium were
compared in Figure 2.21. The day 1 swelling ratios, Q, were significantly different for all
Ca#6 concentrations when analyzed with independent t-tests. However, there was no
difference between the day 7 swelling ratios. This indicates that at earlier time points the
hydrogels are more susceptible to ion exchange with their surrounding media, and
eventually reach an equilibrium by day 7.
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The significant differences seen in the higher molecular weight alginate, but not in the
lower molecular weight, imply that the density of the polymer network does have an
effect on the water-absorption capacity of the hydrogel. These studies suggest that as the
density of the polymer network increases, so do the water absorptive properties of the
material. This was further validated by the comparisons of the high- and low-molecular
weight alginates in Figure 2.19.
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Cell Distribution Within Bioprinted Droplets
Cell homogeneity was determined by sectioning the bioprinted droplets into quadrants, as
well as concentric circles to evaluate the distribution of cells within different biomaterials
after the bioprinting process. The cell distributions were then analyzed in SPSS Statistics
software using ANOVA to determine if there was any difference with respect to cell
density in the different areas.
For the NHDFs suspended in 5% LF20/40 alginate (Figure 2.22) bioprinted droplets
sectioned into quadrants (n=10) the calculated F value was 1.572 (P<0.215), which was
less than the critical value of F (2.901). Therefore, there was no difference between cell
distribution in the different quadrants indicating a homogeneous cell distribution
throughout the bioprinted droplet.
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For the droplets sectioned into concentric circles (n=10) the calculated F value was 6.463,
P<0.005, which indicates there is a difference in cell distribution between the different
concentric regions. To determine which regions were different from one another,
independent t tests were performed in SPSS statistics to compare all of the groups. When
the outer and middle rings were compared, the calculated P value was P<0.234, which
suggests there was no difference in number of cells between these two groups. When the
outer and inner concentric rings were compared, the calculated P value was P<0.332
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indicating no difference between these groups. Finally, when the middle and inner
concentric rings were compared, the P value was found to be P<0.027. Therefore, there is
a significant trend of a denser cell population within the middle concentric ring as
compared to the inner-most portion of the bioprinted droplet for this bioink.
For the 0.62% collagen and 4% LF20/40 alginate blend (1:1; n=5; Figure 2.23) sectioned
into quadrants the calculated F value was 2.101 (P<0.140), which was less than the
critical value of F for P<0.05. For the droplets sectioned into concentric circles the
calculated F value was 1.083 (P<0.369), which was also less than the critical value of F
for P<0.05. Therefore, there was no difference in the distribution of cells between the
different quadrants or concentric circles of the bioprinted droplets using the
collagen/alginate blend bioink.
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The F value calculated for NHDFs suspended in 5% LF10/60FT alginate (n=9; Figure
2.24) bioprinted droplets sectioned into quadrants was 1.963 (P<0.139), which was less
than the critical value of F for P<0.05, indicating there was no difference in cell
distribution between the different quadrants of the bioprinted droplets. For the NHDFs
suspended in 5% LF10/60FT alginate sectioned into concentric circles, the calculated F
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value was 23.084, which was greater than the critical value of F, 19.45, for P<0.05.
Therefore, there was a difference in cell distribution between the different regions of the
bioprinted droplet. To determine which regions were significantly different from one
another, independent t tests were run in SPSS statistics.
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When the inner and outer rings were compared, the significance was P<0.001925 with a
definite trend of more cells being located in the inner concentric circle as compared to the
outer. When the outer and middle rings were compared, the significance was P<0.000267
with more cells being located in the middle ring than the outer. Finally, when the middle
and inner rings were compared the significance was P<0.180344 indicating there was no
difference in the cell distribution between these two regions. Therefore, for the 5%
LF10/60FT bioink there is a trend of cell distribution towards the interior of the
bioprinted droplets.
Cell Viability in Bioprinted Constructs
Cell viability, one of the requirements of a successful bioprinting technique, was
analyzed 1 hr and 8 days post-printing. High cell viability is essential for fabricating
biomimetic constructs and is a direct representation of an adequate bioink. RGD peptide
conjugation improves cell viability over extended periods of time by promoting cell
spreading. Fluorescent microscopy was used to quantify cell viability in constructs after
the printing process. Alginate bioink with a concentration of 15% and oxidation of 5%
had average day 0 viability of 98%, day 4 of 96%, and day 8 of 95% (Figure 2.25). An
independent t test was performed to determine the significance of the difference between
cell viabilities on days 0 and 8, and a P-value of P<0.002 suggests the viability
significantly increased over the culture time period.
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These results indicate the deposition technique of the direct-write bioprinter extrudes
cells gently enough to produce constructs that remain viable during and after the printing
process. The high cell viability shows the 5% oxidation and 15% concentration alginate
bioink was a suitable vehicle for cell deposition and provided an adequate environment
for cell-survival. Similar cell counts in each of the areas showed a homogeneous cell
distribution in the alginate bioink, a fundamental aspect of printing resolution.
Cell Proliferation in Bioprinted Constructs
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Most tissues have complex combinations and gradients of extracellular matrix
constituents, each with specific biological and mechanical influences. A biomaterial
should be biomimetic of the native environment and facilitate cellular functions. The high
porosity of the alginate scaffold allows the cells to communicate and network with each
other, and may also facilitate the flux of nutrients and metabolites between the scaffold
and its surrounding environment. Cell adhesion to the extracellular matrix is a
preliminary phase of tissue formation that happens before cell proliferation and the
organization of extracellular matrix molecules into functional tissue. The proliferation of
cells plays a vital role in wound healing and tissue growth, and is therefore a very
important factor when analyzing bioprinted constructs for tissue engineering applications.
The RGD-conjugated alginate enhanced cell attachment in printed constructs, leading to
improved cell spreading and proliferation. The proliferation of cells in the printed
scaffolds was quantified by counting three separate areas on days 0 and 8 (Figure 2.26).
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The overall cell proliferation was found to be 219.674% after 8 days of culture. These
results signify the scaffold has adequate biocompatibility to be used as a synthetic
extracellular matrix for delivering cells to repair damaged or nonfunctional tissue.
2.8 DISCUSSION
Presented here is a 3D robotic bioprinter that reliably and consistently dispenses
homogenous drops of individual cells or cells mixed with biomimetic hydrogels (37).
There are critical aspects of the design process that impact the generated construct’s
biomimetic function (35,36). The ability to control the temperature of the biomaterial and
substrate is essential for the gelling mechanism of the hydrogels and the maintenance of
their mechanical properties, therefore influencing cell distribution, proliferation, and
differentiation within the hydrogel. Organs consist of many cell types, so the multiple
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dispensers are critical for producing heterogeneous, tissue-like structures. The computeraided design of the external architecture allows the production of custom tissue
substitutes for distinct wounds or tissues. This is essential for the development of patientspecific replacements. The internal architecture is equally important because it affects the
cell-cell relationships within the structure by placing the proper cells in intimate contact
with each other and allowing them to form in vivo-like cell-cell junctions. Precise
placement of cells determines how the cells communicate and network with each other to
form vascular networks and mimic their bioactivity in native tissues. Three-dimensional
bioprinting provides homogeneously dispersed cells within the bioink, as well as
excellent precision on spatial placement of the cells themselves (33). Generated scaffolds
also have high local cell densities, which is essential for cell differentiation and the
formulation of extracellular matrix.
The bioprinter implemented here comprises a unique temperature-controlled
environment in which the cells and cell-hydrogel mixtures are not limited by the
necessity of pre-fusion. Under these conditions, the bioprinter is not solely reliant on the
differential adhesion hypothesis. The inclusion of hydrogel materials can help guide the
cell distribution and allow the cells to fuse, or not, depending on the properties desired
for specific experimentation. The selection of biomimetic hydrogels for cellencapsulation also has a profound effect on cell phenotype. Materials are known to have
an effect on cell attachment, as well as cell size and morphology (36). The rheological
characteristics, such as viscosity, of hydrogels dictate their influence on the cellular
microenvironment (35). Native alginate is inert and does not readily communicate with
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cells participating in the control of phenotype. However, using alginates that are
chemically modified via peptide conjugation and oxidation, produces constructs with
controlled degradability and increased cell attachment, migration, and proliferation (39).
Altering the physiochemical properties of a biomaterial can influence tissue development
in vivo (35,41).
Three-dimensional bioprinting using a fluid-dispensing, direct-write machine is
limited by the degree of resolution of printed constructs, the availability of hydrogel
materials, initial cell death post-printing, and the ability to vascularize the biomimetic
scaffolds (32,41,42). An important feature of the bioprinting is its resolution. Every
printing method is defined by the lower technical limit size of the smallest achievable
details. There is a dynamic relationship between the lower limit size and attainable scale
of the printed construct: the higher the resolution of the minute details, the smaller
maximum construct size (9). The bioprinter is capable of depositing volumes as small as
230 nL in highly specific and organized patterns, giving it a higher resolution than similar
machines. Hydrogels have been commonly used in bioprinting due to their
hydrophilicity, biocompatibility, structural similarity to the extracellular matrix, and ease
of modification (10-16). The high-water content of hydrogels improves their
biocompatibility, but greatly reduces their mechanical strength and printability (33).
There is a lack of optimal hydrogels with the appropriate mechanical properties for fluid
delivery during bioadditive-manufacturing extrusion. Therefore, there is a large demand
for developing hydrogels that are immunologically inert, have cytocompatible gelation
mechanisms that can be successfully extruded using fluid delivery, and also produce a
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cell-laden matrix with an optimal range of mechanical properties (2). Before the printing
process, the cell-laden hydrogel bioink must be stored in the syringes for an amount of
time, compromising the cell’s viability (33). During the printing process, the shear stress
induced on cells during extrusion can also be harmful to their viability (2,43). The
bioprinter is able to produce highly viable (>90%) constructs, therefore overcoming the
issue of initial cell death.
Vascularization plays a vital role in transmitting, supporting, or preserving the
biomimetic function of bioprinted constructs (43). The diffusion of oxygen is 100 −
200𝜇m; therefore, in larger bioprinted constructs hypoxia is a concern (9). Conventional
techniques are incapable of producing constructs with embedded vasculature, greatly
limiting the size of producible scaffolds. The cell viability assessment of the bioprinter
showed significant cell proliferation in the printed constructs over 8 days. Therefore, the
technique proves its ability to generate scaffolds that allow cell growth, communication,
and the formation of networks, requirements of vascularization.
The bioprinter provides the ability of using a variety of materials to quickly
deposit cell-laden hydrogels in specific patterns. While this technique produces
heterogeneous constructs with tunable properties, it is incapable of concurrent deposition,
i.e. multiple syringes depositing at once, and reactive mixing, such as core-shell
bioprinting discussed in chapter one. For some biomaterials, this deposition method
would enhance the gelation mechanism and shorten the time for scaffold production (35).
The addition of a multi-syringe dispenser could allow a broader range of biomaterials for
the biofabrication technique. Investigation of cell activity in bioprinted constructs over a
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longer period of time would provide more information about hydrogel characteristics, cell
network formation, and vascularization of the constructs. These methods provide the
possibility of producing vascularized replacements for future applications because the
constructs are produced with high local cell densities and allow cell-cell interactions,
which improves the likelihood of post-implantation survival (12,29).
The bioprinter’s deposition method described can further involve robotically
positioning and driving the three dispensers to deposit a plurality of biological materials
on top of previously deposited materials in a predetermined pattern. This step can be
repeated using ascending patterns until a three-dimensional organ or tissue is produced.
Therefore, the Palmetto Printer is suitable for reliably dispensing cell-laden hydrogels to
create a three-dimensional construct that is capable of retaining vasculature and high cell
viability, and could be used in a variety of future tissue engineering applications.
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CHAPTER THREE
SCAFFOLD-FREE TISSUE ENGINEERING
The field of tissue engineering advances an exciting array of solutions for organ
repair and wound healing. However, to realize this potential, several hurdles must be
overcome. Vascularization is arguably the most important practical limitation in tissue
engineering, imposing both dimensional and time constraints on the technology.
Vascularization and fast anastomosis with the host are essential in engineering cellular
constructs that survive once implanted, as well as tissue maintenance and regeneration.
Endothelial cell migration and physiological growth of new blood vessels in vivo has
been reported to occur at ~5 um/hour due to the availability of oxygen, which is limited
to a diffusion distance of 150 − 200𝜇m from a supplying blood vessel (Figure 3.1) (4243). This diffusion limit is relative to the distance between mammalian cells and an
adjacent vascular bed (Lovett). With the clinical need being for larger engineered tissues,
a major focus in the tissue engineering field has been on designing constructs with preexisting vascular architectures or, more recently, prevascularized constructs.
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Vascularization of an avascular tissue, or a tissue graft, can be modeled by a wellordered series of events (Figure 3.2), starting with (1) endothelial cell activation, (2)
migration of endothelial cells and remodeling of the implant stroma, (3) Primitive
network formation (4) anastomosis of host/implant endothelial structures, (5) Network
remodeling (6) Lumen formation within the endothelial architecture, and (7) maturation
of vessels through recruitment of mural cells. This leads to formation of a blood-perfused
vascular pedicle in an implant. Depicted is the expected entry point of different implant
types, with preceding development either occurring in vitro or supplied by donor.
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Current engineered grafts, such as the bioprinted constructs discussed in chapter 2, are
absent of any vascular architecture, forcing them to enter the vascularization pipeline at
the earliest time point. Rather than incorporating intricate microvessel architectures into
our bioprinted constructs, we began investigating scaffold-free fabrication methods.
Scaffold-free tissue engineering aims to produce physiologically-relevant threedimensional multicellular constructs without the use of a scaffold.
3.1 SCAFFOLD-FREE CELLULAR SELF-ASSEMBLY
Scaffold-free engineering techniques rely on the inherent capacity of cells to
migrate and form intercellular connections. Adherent cells, like endothelial cells and
fibroblasts, depend on the formation of these intercellular as well as extracellular matrixcellular connections for survival. When adherent cells are placed in an environment that
lacks a surface for adhesion or a substrate, the cells will aggregate and undergo the
process of self-assembly. During the process of self-assembly, suspended cells form
three-dimensional multicellular spheroids. This process mimics processes known to occur
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during embryogenesis, morphogenesis, and organogenesis in vivo (Achilli, 2012). The
produced multicellular spheroids have similar architectural and functional characteristics
of native tissues.

3.2 PREVASCULARIZATION: PRIMARY NETWORK FORMATION
To sustain larger tissue engineered constructs, an intact vascular pedicle
consisting of an inlet, outlet, and a perfusable capillary bed, must either pre-exist or form
rapidly upon implantation. Prevascularization has recently been explored in tissue
engineering in attempts to accelerate the acceptance of implanted cellular constructs.
These techniques aim to produce implants with a preformed microvasculature prior to
implantation. Prevascularization refers to the in vitro assembly of primitive endothelial
networks resembling a capillary bed.
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In recent years two strategies for vascularization of tissue engineered constructs
have been explored: angiogenesis and inosculation. The angiogenesis approach relies on
the ingrowth of vascular sprouts from the host microvasculature (indicated by the red
vessels in Figure 3.4A) into the implanted construct, which overtime fuse together to
form a new microvascular network (12). This process is highly dynamic and must
progress through the entire vascularization pipeline depicted in Figure 3.1. The
inosculation approach incorporates a preformed microvascular network prior to
implantation (depicted by the blue vessels in Figure 3.4B) that forms interconnections, or
inosculates, with the host vasculature to get a fully blood-perfused vessel within a short
amount of time (12).
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Laschke and Menger make a useful distinction between angiogenesis and
inosculation that explains the utility of prevascularization: angiogenic sprouting, while
potentially faster than de novo vasculogenesis, is still a slow process, whereas
inosculation, or the merging of existing microvessels into larger diameter vessels, occurs
more rapidly (12,14,43-44). Specifically, in vivo microvessel growth occurs at a peak rate
of 5

µm
Chr (12). Therefore, spanning an entire implant exceeding dimensions of a few
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hundred micrometers at this rate is too slow to prevent ischemic damage, as hypoxia
peaks in skeletal muscle at approximately eight hours (9,12).
3.3 DEVELOPMENT OF NOVEL SCAFFOLD-FREE PREVASCULARIZED
ENDOTHELIAL-FIBROBLAST CONSTRUCTS
Engineering these vascularized implants in vitro requires the use of multiple cell
sources to form the multiple components of vessels including the lining of the vessels,
which is predominantly made up of endothelial cells, and the supporting cellular network
(41). We have developed and previously reported on the anastomotic potential of a
scaffold-free prevascular implant model that is formed from the coculture of human
adipose microvascular endothelial cells (HAMECs) and normal human dermal fibroblasts
(NHDFs) (5,23,25-26). We use primary human adipose derived endothelial cells to
ensure clinical translatability, where an autologously derived population of cells can be
re-implanted in a patient with minimal morbidity due to immune compatibility
complications. The adult fibroblasts create the extracellular-rich stroma necessary to
support a vascular bed and provide additional proangiogenic stimuli (22). Mature
endothelial cells, while capable of forming spontaneous capillary like tubes in vitro,
appear to require consistent input of proangiogenic environmental signaling. Fibroblasts,
through constitutive expression of vascular endothelial factor (VEGF), basic fibroblast
growth factor (bFGF) and angiopoitin-1 (Ang-1), address this basic need (22). The
presence of fibroblasts corresponds to an increased microvessel density within an implant
and stabilization of vessels by signaling endothelial cell to express smooth muscle actin
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(16). Other exctacellular matrix proteins deposited by the fibroblasts such as laminin,
collagen type I and collagen type IV are needed for vessel maturation (10).
We have previously reported that a specific 1:4 ratio of human microvascular
endothelial cells and fibroblasts maximizes the density of endothelial cords when allowed
to self-assemble in a scaffold-free non-adherent environment. Increasing the density of
fibroblasts resulted in endothelial clusters without cords, and increasing density of
endothelial cells resulted in structures lacking avascular stromal areas consistent with a
vascular bed (23). Additionally, these endothelial cords were shown to organize into
vascular networks with distinct directional orientations that reflect self-assemblymediated tension (25; Figure 3.5).

Within 3 days of in vitro culture in an agarose mold, the coculture generated an
extracellular matrix containing laminin, type I collagen, and fibronectin. The interplay
between ECM components, such as laminins and fibrillar collagen, and cell surface
integrins play a key role in vascular lumen formation (24).
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Due to the diffusional limits of oxygen and nutrients to the interior of implanted
constructs, we wanted to take a more systematic approach to investigate the
vascularization process and how engineered constructs get perfused once implanted. The
literature reports findings from later time points post-implantation, spanning from a few
days to even more than a week post-implantation, to assess graft acceptance. However,
this data is incomplete as it does not evaluate the dynamics of vascularization at early
time points following implantation. Additionally, ischemic damage to tissues occurs
within a time span of hours rather than days, necessitating a focus on processes impacting
vascularization within a 24-hour post-implantation window. Therefore, we wanted to
investigate the early temporal kinetics of vascularization, i.e. <24 hours postimplantation, of implanted cellular constructs, in order to discern the immediate events
happening post-implantation. Specifically, we hypothesized that the existing selfassembled primitive network of the Scaffold-free Prevascularized Endothelial-fibroblast
Constructs (SPECs) will allow earlier host-implant anastomosis and increased presence
of lumen containing vessels in the interior of the implants by 24 hours compared to
avascular grafts, such as fibroblast spheroids.
3.4 MATERIALS AND METHODS
Formation of Non-adherent Agarose Molds
A 2% (w/v) agarose solution is made by dissolving the agarose in deionized water. To
sterilize the solution, it is autoclaved on the liquid cycle for thirty minutes. The geometry
of the agarose mold is determined by the computer-aided design used to create the
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negative in which the agarose is gelled around. This provides the opportunity for using
patient-specific images to create physiologically-relevant SPECs in the future.

Cell Culture
Human adipose microvascular endothelial cells (HAMEC) (ScienceCell, Carlsbad, CA,
7200) were cultured in T75 cell culture flasks with endothelial growth medium-2 (EGM2) (Lonza, Allendale, NJ, CC-3156 & CC-4176) until reaching 80% confluence. Normal
human dermal fibroblasts (NHDF-Ad) (Lonza, CC-2511) were cultured in Fibroblast
growth media-2 (FGM-2) (Lonza, CC-3131 & CC-4126). Cells were collected between
passages for use in experiments.
Formation of Scaffold-free Prevascularized Endothelial-fibroblast Constructs
We have developed and previously reported on the anastomotic potential of a scaffoldfree prevascular construct that is formed from the coculture of human adipose
microvascular endothelial cells (HAMECs) and normal human dermal fibroblasts
(NHDFs) (5). In previous work, Czajka, et. al. determined the appropriate ratio of
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fibroblast to endothelial cells to be 4:1 (5,23,25-26). The scaffold-free prevascularized
endothelial-fibroblast constructs (SPECs) were modifications of the protocol established
by Czajka and Drake (23). Rod-shaped troughs of 0.9 cm length by 0.1 cm width by 0.5
cm depth were constructed in 2% UltraPure Agarose (Invitrogen, Carlsband, CA, 16500100) and high density 4:1 mixtures of 720,000 NHDF-Ad cells and 180,000 HAMECs
were pipetted into the troughs of the agarose mold. Cells were then cultured in a 2:1
mixture of FGM-2 and EGM-2 for 3 days. Implants were either collected in Dulbecco’s
Phosphate Buffered Saline for use in surgical implantation or collected and fixed in 4%
paraformaldehyde for histology. Fibroblast-only spheroids (FOS) were constructed
similarly with 900,000 NHDF-Ad and no HAMECs. Silicone fragments of rectangular
box dimensions of 0.6 cm by 0.1 cm by 0.1 cm (to match the eventual dimensions of the
cell-based rods) were autoclaved and stored in DPBS in preparation for implantation.
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Immunohistochemistry Analysis of SPEC
Tissue sections were fixed in 4% paraformaldehyde solution for thirty minutes
and subjected to hematoxylin and eosin staining, direct or indirect immunofluorescence
labeling. Tissue sections were directly labeled with Hoescht 33342 nuclear stain
(Molecular Probes, 1:10,000), and Alexa FluorTM phalloidin 488 (ThermoFisher
Scientific A12379, 1:500) for F-actin. Selected sections were stained with primary
antibodies to von Willebrand Factor (Abcam, Catalog# ab6994, 1:1000), CD31 (Abcam
ab28364, 1:50), human CD31 (monoclonal antibody) (R&D Systems BBA7, 1:25),
smooth muscle actin (ThermoFisher Scientific PA5-19465, 1:1000). Primary antibodies
were fluorescently tagged with the secondary antibodies Alexa FluorTM goat anti-mouse
488, goat anti-rabbit 546, goat anti-mouse 546, and goat anti-rabbit 633 (ThermoFisher
Scientific, A-11001,11035,11030,21070, 1:500). Sections were mounted on Colormark
Plus microscope slides in Prolong Gold antifade reagent (Molecular probes P36934).
Western Blot Analysis
SPECs and FOS were collected after 1, 2, and 3 days of culture in 2% linear agarose
molds as previously described. Samples were snap frozen, and mechanically
homogenized in RIPA lysis buffer with protease inhibitor cocktail. Samples were
maintained in constant agitation for 2h at 4°C, centrifugated for 20 min at 16,000 g at
4°C. Supernatant was stored in fresh tube at -20°C. PierceTM BCA Protein Assay kit
(Thermofisher Scientific 23227) was used to estimate protein concentration for samples
as per manufacturer’s instructions. Prior to gel electrophoresis, samples were diluted in
RIPA buffer to attain 20 ug of protein in 20 uL solution, and further diluted 1:1 in 2x
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Laemmli Sample buffer to attain 40 uL loading volumes. Samples were loaded onto Any
kDTM Mini-Protean® TGXTM Precast Protein Gels. Following protein separation and
overnight transfer onto PVDF membranes, western blots were performed using
antibodies towards GAPDH (loading control) (CalBioChem CB1001, 1:1000), VEGFR2
(Abcam ab39256, 1:900), VE-Cadherin (ThermoFisher Scientific 36-1900, 1:250), vWF
(Abcam, ab6994, 1:500), and DLL4 (Abcam ab7280, 1:1000).
Endothelial Cell Migration out of the SPEC in vitro
To investigate whether the SPEC could promote vascularization, we looked at the
behavior of the embedded endothelial cells when placed in an acellular environment.
Endothelial cells were tagged with GFP following the protocol. In this study, the SPEC
was placed in the center of a well of a cell culture dish and monitored using the
LionHeartFX Live cell imager (Biotek) over 7 days (Figure 3.8).

Microscopy and Quantitative Analysis of Endothelial Cord Organization
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Confocal images were acquired using Leica TCS SP5 AOBS Confocal Microscope
system (Leica Microsystems Inc., Buffalo Grove, IL) and collected as average projected
z-stacks at 20x and 40x magnifications. Stitching was performed using LAS AF v2.6.3
Build 8173 and encompassed the entire visible cross section of each implant. Images
were auto-enhanced and analyzed using ImageJ (NIH, Bethesda, MD). To analyze
endothelial cord organization, stitched 40x (512x512) confocal images of sections stained
with antibodies for vWF and CD31 were segmented as follows. Average projected
images (10um depth) were auto-thresholded in ImageJ (Otsu auto threshold; 29), and
binarized. Perimeter of the implants and endothelial capsule around implants were drawn
freehand. Binary images were used to calculate microvessel area fractions of the implant.
Binary images were skeletonized using an ImageJ plugin, provided by Arganda-Carreras
et al, with branches pruned by lowest intensity voxel (30). Resulting images was used to
calculate number of junctions and vessel branch lengths.
Animal Model Development
Animal procedures were conducted following the approval by Institutional Care and
Animal Use Committee (IACUC) of the Medical University of South Carolina. Fifty-four
Sprague Dawley rats (Charles River Labs, Wilmington, MA) were divided into three
groups: SPECs (n=15), FOS (n=15), and silicone implants (n=15). Nine rats were set
aside for sham surgeries. Surgeries were performed as described by Calder, et al.
Implants were placed in submuscular pocket, with the long axis oriented parallel to the
hind limb running proximal to distal. Five rats within each implant group were sacrificed
at 6hr, 12hr, and 24 hours with muscle excised from the left hind limb en bloc with
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implant or sham surgery, placed in O.C.T. Compound (Tissue-Tek 4853, Torrance, CA)
and frozen at −80℃ for cryosectioning. Muscle from the right hind limb was harvested
for comparison.

Statistical Analysis
Statistical Analysis was performed using IBM SPSS for Windows Version 24.0
(Released 2017, Chicago, SPSS Inc). Levene’s test for homogeneity of variance was used
to determine equality of variances (α=0.05). For data with equal variance between
groups, One-way ANOVA was performed with post hoc application of Bonferroni’s t test
used to compare microvessel density, degree of penetrance of vessels, and branching
density among the three implant types at each time point. For data with unequal
variances, Welch’s one-way ANOVA was performed with Dunnett T3 post-hoc
corrections.
Scalability of the SPEC Technology
The most important part of developing cellular technologies for tissue engineering, is the
feasibility of scaling these constructs to physiologically-relevant sized tissues. To assess
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the possibility of scaling this technology to larger, more complex geometries, we created
a honeycomb structure consisting of the cells equivalent to nine SPECs, including 6.48
million NHDFs and 1.6 million HAMECs.
3.5 RESULTS
In vitro Analysis of Scaffold-free Prevascularized Endothelial-fibroblast Constructs
When we analyzed the SPECs in vitro, we observed a high abundance of primary
vascular networks, indicated by CD31. The minimum requirements for primary network
formation are endothelial cells and synthetic cells, like fibroblasts, that together secrete
extracellular matrix. As indicated here by CD31 there are dense endothelial networks
within these scaffold-free constructs, surrounded by extracellular matrix, indicated by
Phalloidin staining for F-actin (Figure 3.10).
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Rate of Endothelial Cell Migration out of the SPEC in vitro
A time-series image of GFP-tagged HAMECs within the SPECs placed on a tissue
culture plate demonstrated a high degree of motility of the endothelial cells following
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three days of culture, with some cells tracked as traveling over 400 µm in distance within
a 24h time series (Figure 3.11).

Western Blot Analysis
Prior to implantation, the SPECs presented with vWF, VEGFR2 and VE-cadherin as
indicated by (FIGURE 3.12). Control FOS implants displayed negligible levels of these
vascular markers. Western blotting for DLL4, a marker of endothelial tip cell phenotype
showed increased levels at days 1 and 2 of SPEC incubation but decrease by day 3
compared to FOS controls.
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Quantitative Analysis of Endothelial Cord Organization
Implant vascular structures (CD31 or vWF+) were segmented based on
immunofluorescent images of tissue cross sections (10 µm depth) containing the entire
implant cross section as well as an intact muscle/implant interface (Figure 3.13A).
Endothelial structures in direct connection with this interface and the endothelial capsule
surrounding the implant were segmented separately (green) from the vascular structures
found within the interior of the implants (yellow). Total microvessel area fraction, or the
percentage of the implant cross sectional area containing vascular elements, was
calculated for each implant, with comparisons made between implant types at the 6h,
12h, an 24h time points (Figure 3.13B). Microvessel area fraction excluding the
endothelial capsule at the muscle/implant interface was calculated for each implant
(Figure 3.13C). The fraction of endothelial cords that penetrate the implant interior was
calculated by dividing the length of the cords found excluding the capsule vessels by the
total length of the vascular network (Figure 3.13D). This fraction is a surrogate marker
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of the invasiveness of the vessels within and surrounding each implant within the host.
Junction density was calculated as the number of vessel branch points found per um2 of
the implant cross sectional area (Figure 3.13E-F). Similarly branching density was
calculated as the number of branches per um2. These two metrics assess the branching
complexity of the developing vascular networks in each implant type across time.
Microvessel area, junction density, and branch density of SPECs remain significantly
elevated compared to other implants at all time points. Fibroblast spheroids demonstrated
the most growth in terms of microvessel area and penetrating tubule fraction between 12
and 24h with branch density resembling the SPECs at 24h.
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Assessment of Short-term SPEC Implants (<24 hours)
All three implant types developed a CD31 and vWF-positive capsule as early as 6h postimplantation, indicating early endothelialization of the host-implant interface (Figure
3.14). The SPECs showed this capsule interdigitating with internal vascular elements at
6h; however, neither the FOS, nor the silicone showed endothelial cords within the
implant interior at the 6h time point. By 12h, the SPECs displayed larger vessel-like
bands composed of smaller cords penetrating through the implants, some of which
bisected the implants (Figure 3.14). By 24h, many small lumen-like structures were
present at the periphery of the implant connecting with the thicker endothelial capsules
(Figure 3.14).

Mural Cell Involvement
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Mural cells improve vessel stability and reduce vessel turnover. They are recruited later
in the vascularization pipeline, and stabilize vessels by forming connections with the
endothelial cells toward the periphery of the vessels. At the 6 hour time point, there was
very low mural cell involvement. However, by 12 hours there was a significant increase
in mural cell recruitment indicated by the alpha-smooth muscle actin stain (yellow) in
Figure 3.15.

97

Lumen Formation Within Implants
Implanted cells were labeled with CellTracker Blue to distinguish them from the host.
Cd31+structures (red) with apparent lumens are visible within implanted SPEC cells
labeled with Cell Tracker (Blue) at 12 hrs post-implantation (Figure 3.16). These lumens
were not present in the FOS or the silicone implants.

Contributions to the Formed Vascular Networks
Monoclonal anti-human CD31 antibody stain (red) and polyclonal anti-vWF
antibody stain (green) were used to distinguish implant-derived networks from the host to
determine the contributions of each to the vasculature seen (Figure 3.17). Host-derived
vascular networks only stain for anti-vWF, while implant-provided vasculature is tagged
by a colocalization resulting in a yellow label. The internal vasculature of the SPECs was
largely implant derived, as indicated by the monoclonal human CD31 stain (Figure
3.17A). By contrast, the endothelial capsule components in the SPEC and FOS only
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express polyclonal vWF, which labels both rat and human endothelial cells, indicating
derivation from the rat hosts. Vessels in control sections of muscle without a surgical
pocket similarly solely express vWF in their lumens (Figure 3.17B). Host-derived
vascular networks only stain for anti-vWF stain and are visible at the external capsule
surrounding the SPECs and in vessels distal to the implant site in the opposite host hind
limb muscle (Figure 3.17C).

Additionally, at 12-hours post-implantation, penetrating host-derived cords within
the SPECs colocalized with the implant-derived components, indicated by cell tracker
(blue) (Figure 3.18), indicating implant contribution to these endothelial structures.
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Invading von Willebrand factor+ endothelial branches from the endothelial capsule
inosculate with cell tracker positive endothelial cords (magenta) indicating both host and
implant contribution to SPEC vascular network.

Assessment of Long-term SPEC Implants (72 hours)
Implanted constructs show early signs of anastomosis in a rat hind limb muscle. Within 3
days, there was evidence of red blood cell perfusion in the implants with vascular
structures that persisted out to 2 weeks (25). The SPECs were implanted in hind limb
defects, and excitingly by three days post-implantation neighboring satellite cells had
been activated and were migrating towards the muscle defect site (Figure 3.19).
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Applications of the SPEC Technology
To investigate the potential for creating tissue-specific SPECs that are function as the
tissue they are designed to be, Rhett, JM, et. al. incorporated islet cells to see if a
prevascularized bioartificial pancreas could be created (28). Immunoconfocal microscopy
images demonstrated the islet-containing constructs expressed insulin and retained the
microvascular network seen in constructs without islets (Figure 3.20). Note the dense,
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web-like pattern of endothelial cells in both constructs, indicating a robust vascular
network. Importantly, the vascular network surrounds the embedded islets. These results
indicate that the prevascularized bioartificial pancreas is a potential tool for improving
long-term survival of implanted islet cells in vivo.

As another application, we investigated the possibility of creating prevascularized renal
tissue. Murine kidneys were micro-dissected and isolated for living corticomedullary
renal segments (27). These segments were capable of rapid incorporation into the SPEC
and form intact structures (Figure 3.21A). The constructs retained their prevascularized
network shown by labeling with von Willebrand Factor for endothelial cells (Figure
3.21E). However, unlike in the bioartificial pancreas, the prevascular network did not
appear to invade the renal cellular material. Renal epithelial cells were labeled with
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Cytokeratin-18 (green, Figure 3.21B). The constructs were incubated with FITC-labeled
albumin (gray in Figure 3.21C) to test in vitro renal functionality. While there was
resident albumin found away from the segments of embedded renal tissue, there are “hot
spots” in the area of the renal tubular epithelial cells, which are known to take up albumin
that traverses intra-luminally. Therefore, there was successful albumin reuptake in the
renal segment SPEC construct.

Scalability of the SPEC Technology
The most important part of developing cellular technologies for tissue engineering, is the
feasibility of scaling these constructs to physiologically-relevant sized tissues. Here, we
have demonstrated the SPEC can be scaled up into larger, more complex geometries, and
the use of the bioprinter, described in chapter 2, to fabricate these constructs could allow
the creation of much larger and even more complex constructs, including patient-image
derived implants.
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Additionally, in preliminary work investigating the effects of perfusion on SPECs during
their formation in vitro we found that the SPECs were able to readily fuse together to
form larger constructs (Figure 3.23), which retained their vascular networks (CD31, red)
and extracellular matrix components. This offers another potential technique for
expanding this technology to the much-desired larger implants required for tackling the
organ deficiency crisis.
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3.6 DISCUSSION
The timeline of vascular events (Figure 3.2) immediately following implantation
of prevascular tissue is critical to evaluating the success of implant technology. The
observation windows selected in this study were designed to dissect the components of
endothelial organization, cord sprouting, anastomosis, network remodeling, lumen
formation and, ultimately, vessel maturation that occurred early in the in vitro
development of our implant and shortly following implantation. The 6-12h postimplantation window is particularly important as it contains the time points associated
with a peak in markers of hypoxic stress found within autologous full-thickness muscle
flap transplants in prior studies by our laboratory (9).

105

In vitro SPEC development was consistent with non-random organization of a
proangiogenic vascular network
The endothelial cord formation within the SPECs is a non-random process, with
the initial dispersed endothelial cells coalescing into cords throughout the 3-day
incubation period. This migration stands contrary to the popular theory of cellular
behavior termed the differential adhesion hypothesis (32). If the rearrangement was
entirely driven by passive cell adhesion behavior rather than active vascular development
processes, a single interface between endothelial cells within the core and fibroblasts on
the periphery would be observed. This behavior would optimize interfacial energy based
on cell-type specific expression of adhesion molecules such as cadherins (33). Further
evidence of active vessel formation within the implant is provided by western blot data,
through expression of vascular markers such as VEGFR2, VE-cadherin, and vWF. Dll4
expression in implants is consistent with angiogenic and anastomotic potential of
endothelial cells as reported in literature (Figure 3.12; 34-35).
Early 6hr post-implantation period demonstrates rapidity of endothelial capsule
formation around implants, and rapid inosculation of scaffold-free prevascular
constructs to host
One of the major goals of vascular tissue engineering is near instantaneous
perfusion of well-organized cords either by spontaneous in vivo inosculation or surgical
anastomosis (1). While these constructs were not well perfused during the 24h
observation time, endothelial structures extended continuously from the host to the
interior of the SPEC implants within 6h, indicating rapid mobilization of endothelial cells
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to and from the implant. Notably, the SPEC internal structures are derived from human
endothelial cells (Figure 3.17), suggesting that this anastomotic network contains, at least
in part, the preformed primitive network that was developed in vitro.
Additionally, the microvessel vascular area of the SPECs 6h post-implantation is
26±5% which is comparable to the vascular density of the implant prior to implantation
and only approximately 1.2-fold lower than the average microvessel vascular area
fraction throughout the 24h time point (Figure 3.13). The filamentous net-like primordial
form of the network prior to implantation is preserved at 6h post-implantation, with a
high branch point density of approximately 1.2x105 per mm2 implant tissue, resembling
the pre-implantation average branching density of 1.12x105 per mm2. The FOS, on the
other hand, show a significantly lower presence of branching endothelial structures
within the implant stroma, with most of the 8 ± 3% microvessel area confined to the
external capsule. As such, the fraction of the vascular area that includes internally
penetrating tubules in the SPEC is 4.7-fold higher than the fraction within fibroblast-only
spheroids.
The 6 to 12-hour window shows increase in microvessel area in fibroblast only
spheroids and silicone implants but not in SPECs; SPECs show remodeling and fusion
of existing branches
The 6-12-hour window is a period of remodeling in both the SPEC and FOS
implant models. Notably, the band of host-derived endothelial structures around the
implant appear to thicken with a small but significant increase of internally penetrating
branches within some of the FOS. However, the mean microvessel area of the fibroblast
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spheroids, including the capsular components, remains 3.2-fold lower than the SPEC
implants and comparable to that of the silicone implants (Figure 3.13). In other words,
the lack of an existing internal endothelial network in the FOS results in a 12-hour
latency in vascular development of these implants compared to SPECs. The SPECs, on
the other hand, maintain a nearly constant mean vascular area; however, there is a 1.5fold decrease in junctions within the implant and a 2-fold decrease in junctions within the
endothelial capsule. This may be attributed to increased condensation of endothelial
branches to larger structures, an example of which is seen in (Figure 3.14), where a
denser band of endothelial structures appears to pass through the center of the implant
and lumen like structures begin to appear within the SPEC implant cross sections. This
cohesion of existing endothelial cords to form larger multicellular structures is most
consistent with formation of the early vascular tree during embryological vasculogenesis
(36).
Parity between SPEC and FOS angiogenic development by the 24-hour timepoint
By 24h, SPECs and FOS begin to resemble each other in terms of endothelial
organization and mean vascular area, with a greater preponderance of penetrating
endothelial cords in the fibroblast- only spheroids than at previous time points. The
advantage in anastomosis provided by the SPECs, thus, seems to lessen at the 24h time
point, as cords from the peripheral endothelial capsule appear to reach the center of the
FOS. This rapid invasion of vessels in a previously avascular space is itself a surprising
finding. Vascular network can invade on its own as a part of foreign body response, but
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the process has been cited to take a few days to a week (1). The presence of a branching
vascular architecture, however, still seems largely limited to the SPECs.
Evidence of maturation of SPECs at 12-24-hour without perfusion
In angiogenesis, maturation of vessels follows anastomosis and usually occurs
concurrent with perfusion of vascular networks (37). However, in the absence of
consistent perfusion, the SPECs show some indication of vessel maturation. Smoothmuscle actin presenting cells, representing mural, stabilizing cells such as pericytes
around capillaries, or smooth muscle cells around larger arterioles and arteries, are
recruited in the latter stages of angiogenesis, involving a careful interplay between
basolateral elements of endothelial cells such as Tie-2, macrophages, and pericytes.[38, 39]
The SPECs, which present with an apparently disorganized SMA+ cells at the early 6hr
time points show SMA+ cells more fully organized around lumen like structures in the
SPEC at the 12 and 24 hour timepoints (Figure 3.15).
Conclusion
The SPECs retain a set of properties that have inherent therapeutic value when
incorporated into replacement tissue technologies. SPEC spheroids can readily fuse to
form larger spheroids in unconstrained nonadherent conditions and can reshape their
cytoskeletal structures to assume patterns dictated by linear confinements such as agarose
mold.[26] This scalability and shapeable nature, coupled with the primary cord networks
of the SPECs makes them ideal analogues to a vascular stroma or artificial vascular bed
that is inherent to the function of most tissues. The SPECs readily incorporate renal
segments[27] and pancreatic islet cells[28], paving the way for rapidly vascularizable
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artificial renal grafts and bioratifical pancreas. The incorporation of these other cell types
leads to the creation of tissue-specific implants, and could be extended to a multitude of
other tissue-types, as the SPEC serves as the foundation building block of most functional
tissues.
As past studies have reported inosculation of prevascular implants at 2-5 days[40],
vascularization dynamics in literature have not focused on early time points preceding a
few days following implantation. Our study reveals that an earlier observation window
informs us on the relative rapidity of endothelialization around cellular constructs and
reveals that the crucial advantages to a prevascular network might be best seen within 6
to 12 hours of implantation. By this period, the groundwork for a vascular pedicle feeding
the implants has already been laid, with evidence of reorganization towards a more
mature host-implant vascular network. Vascular tissue engineering strategies that proceed
from this point should promote lumen formation and patency of the existing vascular
architecture.
Unmet Challenges of the SPEC Technology
When implanted SPECs and FOS were examined for cell death at 6-hours and 24hours post-implantation, it was evident that the prevascular network in the SPEC did not
alter the viability of implanted cells, as indicated by Tdt dUtp Nick-End Labeling Assay
(TUNEL; green in Figure 3.24A) There was a significant increase in TUNEL+ cells
between the 6 hour and 24 hour time points in both the SPEC and FOS implants
compared to the surrounding rat host muscle (Figure 3.24B).
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Additionally, while these implants get thoroughly perfused by 72-hours (Figure
3.19A-C), there was inconsistent red blood cell presence within the 24-hour window we
were examining (Figure 3.25).

The upregulation of DLL4-expression in SPECS at day 2 is consistent with
increased vascularization of the implant; in contrast, the comparative downregulation at
day 3 of incubation, coinciding with when the implant finishes resolving into a solid
structure, is consistent with quiescence of the prevascular networks. This period of
quiescence may contribute to the latency between anastomosis and in vivo tubulogenesis.
While ideally anastomosis of prevascular implants should only involve inosculation of
externally located cords to the nearby host vasculature, the need to ramp up the
angiogenic machinery of the construct cells might delay further morphogenesis of these
tubes and delay perfusion through the resulting networks. Therefore, further investigation
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into how to drive the SPEC further down the vascularization pipeline should be done to
see if these challenges can be met.
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CHAPTER FOUR
THE ANGIOGENIC POTENTIAL OF SCAFFOLD-FREE PREVASCULARIZED
ENDOTHELIAL-FIBROBLAST CONSTRUCTS
Vasculature is required for tissue maintenance and regeneration in vivo. During
normal tissue development, new vasculature is formed through vasculogenesis and
angiogenesis. These processes are highly dynamic and regulated at multiple levels,
including transcriptional hierarchies and the interactions of proteins, as well as signal
inputs from the extracellular environment (1). In previous work, the Scaffold-free
Prevascularized Endothelial-fibroblast Construct (SPEC) was shown to organize into
vascular networks with distinct directional orientations that reflect self-assembly
mediated tension, and was later shown to quickly anastomose with the host and promote
vascularization upon implantation (2-4). While these cellular constructs have exhibited
successful integration with the host vasculature, they have not reached the phase of
tubulogenesis in vitro. To overcome the unmet challenges of the SPEC seen from our in
vivo studies, we wanted to investigate ways to accelerate the SPEC along the
vascularization pipeline in vitro (Figure 4.1). Specifically, we wanted to investigate
methods for inducing lumen formation, and subsequent tubulogenesis, in the SPEC preimplantation. The ability to drive the SPEC further down the vascularization pipeline in
vitro should improve its engraftment in vivo.
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In recent years there has been a focus on understanding the process of vascular
morphogenesis, and the mechanisms by which endothelial cells form tube networks with
defined lumens (5). There is a distinct difference between the processes of lumen
formation and tubulogenesis. Lumen formation is a local event that involves a small
number of cells opening up a space between them, while tubulogenesis is the formation
of a continuous lumen that spans the entire length of a vessel (6). The formation of these
contiguous tubes via tubulogenesis is required for subsequent blood flow, and for tissue
growth and viability.
4.1 MECHANISM FOR TUBULOGENESIS IN VIVO: CORD HOLLOWING
A proposed mechanism of tubulogenesis in vivo occurs via cord hollowing (6;
Figure 4.2). Prior to lumen morphogenesis, blood vessels consist of coalesced cords of
endothelial cells that lack apicobasal polarity. Luminal space is generated extracellularly
between endothelial cells as they remain tethered peripherally. A possible mechanism for
creating extracellular space between endothelial cells is the clearance of adhesions at the
cord center. Clearance at the cord center can occur either by de-adhesion at the
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apical/luminal membrane, and/or by redistribution of junctional molecules away from the
cord center. Finally, luminal expansion occurs as a result of adhesion junction
rearrangements until a single lumen spans the entire vessel.

Adherens junctions provide strong cell-cell contacts mediated by the cadherincatenin complex and its interaction with the actin cytoskeleton (12). Cadherins are
transmembrane glycoproteins that regulate calcium-dependent cell-cell junctions (11).
Cadherins have important roles in establishing cell growth, migration, and polarity, as
well as regulating tissue morphology and cell differentiation (9,11). Adherens junctions
located at homotypic endothelial cell-cell contacts regulate endothelial cord permeability,
and play an essential role in cord hollowing (8). These junctions are involved in the
activation of many subsequent signaling cascades depending on the complexes formed.
There are two primary cadherins expressed in the endothelium: Vascular
endothelial cadherin (VE-Cadherin) and Neural cadherin (N-Cadherin). These adherens
junctions have distinct functions in vascular maintenance. VE-Cadherin is the principal
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endothelial-specific adherens junction molecule present in all vascular beds, and is
essential for vascular morphogenesis (9). Its expression in endothelial cells is localized to
homotypic cell-cell contacts, while N-cadherin is distributed throughout the entire cell
membrane (11). This dispersion of N-cadherin to extra-junctional regions of the
endothelial cell is regulated by VE-cadherin expression, and is proposed to be involved in
vessel stabilization that occurs through interactions between endothelial and mural cells,
such as pericytes and vascular smooth muscle cells, which helps stabilize vessels by
anchoring the endothelium (9,11).
Catenin recruitment to adherens junctions, specifically, the p120-catenin regulates
cadherin turnover by regulating their entry into the degradation endocytic pathway (13).
N-cadherin controls the levels and cellular distributions of p120-catenin in human
endothelial cells, and thereby regulates VE-cadherin. Luo, et. al. did studies in Human
umbilical vascular endothelial cells (HUVEC) and showed that a knockdown of Ncadherin resulted in loss of VE-cadherin in endothelial cell-cell junctions, and that levels
of junctional and non-junctional p120-catenin were significantly reduced (12). Therefore,
both of these cadherins play critical roles in vasculogenesis and tubulogenesis by
modulating adherens junctional components, and subsequent endothelial cell behavior.
In response to angiogenic stimuli in vivo, endothelial cells undergo dynamic
rearrangements of cell-cell junctions, while simultaneous maintaining their barrier
function (8). This coordinated response is dominantly regulated by the adhesion
molecules located at intercellular junctions. Specifically, Vascular Endothelial Growth
Factor-A signaling is of interest for inducing lumen formation, and subsequent
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tubulogenesis, in the SPEC because it regulates the levels of VE-cadherin at endothelial
cell-cell junctions (7,8,10).
4.2 Vascular Endothelial Growth Factor-A (VEGFA) Signaling
Vascular Endothelial Growth Factor-A (VEGFA) is the most critical regulator of
vasculogenesis and angiogenesis (7,8,10,15). VEGFA signaling mediates immediate
responses, like vascular permeability, and long-term responses, such as endothelial cell
survival, migration, and proliferation (10). Reduced production of VEGFA results in
decreased angiogenesis, and is thought to contribute to impaired tissue repair. VEGFA
and their receptors are critical regulators of new vessel development and the remodeling
of existing ones (10). Blood vessel homeostasis is regulated by VEGFA, which in turn
controls endothelial cell functions within the vessels.
There are three receptors, VEGFR1, VEGFR2, and VEGFR3, that VEGFA can
interact with. These receptors are regulated on numerous levels: the receptor expression
levels, availability and affinity for binding to its different ligands, the presence of coreceptors, the rate of cellular uptake, and extent of degradation and speed of recycling
(10). VEGFR2 is the major signaling receptor in vascular endothelial cells, and is the
main transducer of VEGFA effects on these cells differentiation, proliferation, migration,
and formation of the vascular tube (10). VEGFR1 is expressed by monocytes and
macrophages, and is not required for endothelial cell functions. VEGFR1 actually binds
to VEGFA with a ten-fold higher affinity than VEGFR2, however it has poor kinase
activity, and may act as a negative regulator of VEGFR2 by capturing VEGFA in order to
spatially regulate VEGFR2 signaling and the formation of angiogenic sprouts (10).
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VEGFR1 is majorly involved in regulating monocyte migration during inflammation.
VEGFR3 is expressed by lymphatic endothelial cells and does not play a major role in
tube-formation, in vivo (10).
Of specific interest to us, VEGFR2 regulates VE-cadherin expression at
intercellular junctions through VEGFA-VEGFR2-activated SRC signaling. Upon
VEGFA-VEGFR2 binding, the receptor gets dimerized and then stabilized through
interactions between membrane-proximal Ig-like domains, which allows
trans/autophosphorylation of intracellular tyrosine residues. Specifically, the Y951
residue, located in the kinase inert domain of the VEGFR2 receptor, gets phosphorylated,
which binds to the SH2 of Tsad that in turn recruits and binds to the SH3 domain of Src,
activating Src (Figure 4.3). Src activation is dependent on the phosphorylation of residue
Y951, and regulates vascular permeability, cell-matrix components, and cell adhesion
(10). The activated Src phosphorylates VE-cadherin at the Y658 residue of the
cytoplasmic domain, which disrupts the binding of p120-catenin (13). This dissociation
of p120-catenin results in VE-cadherin endocytosis and results in opening paracellular
junctions and increases vascular permeability (8,13).
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4.3 Sphingosine-1-Phosphate (S1P) Signaling
Sphingosine-1-phosphate (S1P) is a bioactive lipid that stimulates both
endothelial cells and fibroblasts. In vitro, Sphingosine-1-Phosphate (S1P) stimulates
endothelial cell proliferation and survival, migration, capillary-like tube formation, and
regulates the endothelial barrier permeability (14,15). In vivo, S1P binds to its receptor
(S1P1) on endothelial cells to stimulate angiogenesis, and promotes the coverage of
nascent vessels with mural cells for stabilization. S1P has also been reported to be
involved in the stabilization of N-cadherin-mediated endothelial cell-mural cell
interactions (12). S1P has been indicated as a key player in stabilizing N-cadherin-
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mediated endothelial cell-mural cell interactions both in vitro and in vivo (12). The
maturating and barrier-protecting actions of S1P inhibit tissue edema and is predicted to
produce synergistic therapeutic effects with other angiogenic factors, like VEGF (14,15).

Due to the known pro-angiogenic effects of and potential crosstalk between these factors,
exogenous administration of VEGF or S1P into the SPEC is predicted to accelerate in
vitro angiogenesis. We hypothesize this dosing regimen will initiate lumen formation via
cell-cell junctional rearrangements, which stimulates endothelial cell polarity and in turn
recruits essential components of the tubulogenesis machinery to the site of lumen
formation (7).

123

4.4 MATERIALS AND METHODS
SPEC Formation
The scaffold-free prevascularized endothelial-fibroblast constructs were created as
described previously in chapter 3. Briefly, a high-density cell suspension of 1:4 human
adipose microvascular endothelial cells (HAMEC, ScienCell) and normal human dermal
fibroblasts (NHDF, Lonza) were seeded in a non-adherent agarose mold and cultured for
three days. The rod-shaped SPEC with dimensions of 1 mm wide by 6 mm long, required
9x105 total cells.
Preparation of Vascular Endothelial Growth Factor-A and Sphingosine-1-Phosphate
Vascular endothelial growth factor-A (VEGFA, R&D Systems Cat#293-VE-010) was
prepared following manufacturer's instructions. Sphingosine-1-phosphate (Sigma-Aldrich
Cat#S9666) was also prepared following the provided protocol.
Dosing Regimen of SPECs with exogenous growth factors
We decided to treat our SPECs at different time points during their formation, while they
are undergoing the process of self-assembly. We seeded the cells in the non-adherent
agarose molds at D.0. After 24 hours, we treated our constructs with VEGF as a D.1
treatment by incorporating either VEGFA or S1P in the media. We harvested these
constructs on D.3. As a second treatment group, we treated our SPECs 48 hours after
seeding them into the molds, as a D.2 treatment. These constructs were also harvested on
D.3.
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Immunohistochemistry Analysis of SPECs
Tissue sections were fixed in 4% paraformaldehyde solution for thirty minutes and
subjected to hematoxylin and eosin staining, direct or indirect immunofluorescence
labeling. Tissue sections were directly labeled with Hoescht 33342 nuclear stain
(Molecular Probes, 1:10,000), and Alexa FluorTM phalloidin 488 (ThermoFisher
Scientific A12379, 1:500) for F-actin. Selected sections were stained with primary
antibodies to human CD31 (monoclonal antibody) (R&D Systems BBA7, 1:25). Primary
antibodies were fluorescently tagged with the secondary antibodies Alexa FluorTM goat
anti-mouse 488, goat anti-rabbit 546, goat anti-mouse 546, and goat anti-rabbit 633
(ThermoFisher Scientific, A-11001,11035,11030,21070, 1:500). Sections were mounted
on Colormark Plus microscope slides in Prolong Gold antifade reagent (Molecular probes
P36934).
Western Blot Analysis
Treated SPECs were collected after their appropriate culture times in the 2% linear
agarose molds as previously described. Samples were snap frozen, and mechanically

125

homogenized in RIPA lysis buffer with protease inhibitor cocktail. Samples were
maintained in constant agitation for 2h at 4°C, centrifugated for 20 min at 16,000 g at
4°C. Supernatant was stored in fresh tube at -20°C. PierceTM BCA Protein Assay kit
(Thermofisher Scientific 23227) was used to estimate protein concentration for samples
as per manufacturer’s instructions. Prior to gel electrophoresis, samples were diluted in
RIPA buffer to attain 20 ug of protein in 20 uL solution, and further diluted 1:1 in 2x
Laemmli Sample buffer to attain 40 uL loading volumes. Samples were loaded onto Any
kDTM Mini-Protean® TGXTM Precast Protein Gels. Following protein separation and
overnight transfer onto PVDF membranes, western blots were performed using
antibodies towards GAPDH (loading control) (CalBioChem CB1001, 1:1000), VEGFR2
(Abcam ab39256, 1:900), vWF (Abcam, ab6994, 1:500), DLL4 (Abcam ab7280,
1:1000), Laminin (Abcam ab11575, 1:200), N-cadherin (Abcam ab98952, 1:200),
VEGFA (Abcam ab46154, 1:200), Cdc42 (Abcam ab187643, 1:100), and Podocalyxin
(PODXL, Abcam ab150358, 1:300). GAPDH was used as a loading control for all
samples.
4.5 RESULTS
Immunohistochemistry Analysis of Treated SPECs
VEGF-treated SPECs
There were distinct differences between the untreated SPEC control, the D.1 VEGFtreated SPEC, and the D.2 VEGF-treated SPEC. There was no lumen present at the
interior of the untreated SPEC (Figure 4.6A). A singular, small central lumen was
present in the D.1 VEGF-treated SPECs that was surrounded by organized endothelial
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cells (CD31, red; Figure 4.6B). The D.2 VEGF-treated SPECs had a very large central
lumen with densely packed endothelial cells surrounding the luminal area (Figure 4.6C).
This could be attributed to the high pro-angiogenic potential of the SPEC at this time
point during its normal formation in vitro, as indicated in the previous chapter by high
DLL4 expression at this time point. Due to this, we believe the SPEC is most responsive
to growth factor treatments at this time point during its formation.

We also analyzed these constructs to see if there were endothelial cell-cell junction
rearrangements in response to the VEGF treatment by looking at the expression and
density of these networks (CD31, red; Figure 4.7). The untreated SPEC controls have
endothelial networks that span across the entirety of the constructs, including the most
central interior regions (Figure 4.7A). The VEGF-treated SPECs, however, have an
obvious disruption of these networks at the interior of the constructs. This is indicative of
VE-cadherin, the major endothelial cell-cell junction regulator, internalization, which
follows the proposed process of cord hollowing.
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S1P-treated SPECs
In contrast to the single, central lumen found in both of the VEGF-treated SPECs, we
found multiple smaller lumens present at the center region of the S1P-treated SPECs
(Figure 4.8).
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We also compared the expression of F-actin (indicated by phalloidin staining) of the S1Ptreated SPECs to the untreated SPEC control. We found that there was a much more
dense F-actin network surrounding the luminal areas of the S1P-treated SPECs that was
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not as dense as the untreated controls (Figure 4.9). This indicates the fibroblasts began
secreting more extracellular matrix in response to the S1P treatment.

Additionally, the F-actin fibers (green) and endothelial networks (red) in the S1P-treated
SPEC appear more directionally aligned around the luminal area (Figure 4.9).
Western Blot Analyses of VEGF-treated SPECs
Podocalyxin (PODXL) is a marker of the early luminal surface. This molecule gets
shuffled to the interior surface of the forming lumen. It is a charged molecule, and it’s
presence at the interior luminal wall of newly-forming vessels is indicative of established
polarity and the indictment of luminal expansion. Notably, we found that PODXL
expression was upregulated in the VEGF-treated SPECs, indicating these constructs have
established polarity and the cells at the interior are beginning to rearrange to permit
luminal expansion through the entirety of the constructs (Figure 4.10).
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In our analysis for vWF, we found that the VEGF-treated SPECs had a significant
increase in expression, as compared to the untreated controls (Figure 4.11). This finding
was surprising, and may be due to the densely packed endothelial cells surrounding the
luminal region. The cells in this area serve to maintain the endothelial barrier integrity,
while the interior cells undergo rearrangements to form a luminal space. Cdc42 is a small
GTPase that induces vesicle formation and the formation of a luminal area. We found its
expression was also increased in VEGF-treated SPECs. The expression of Cdc42 could
indicate another mechanism participating in the formation of lumens in these treated
constructs: vesicle fusion. Further investigation will be done in future work. We
additionally found that N-cadherin expression was increased in only one of our treated
constructs, which could be due to the disruption of VE-cadherin junctions, therefore cellcell adhesions rely on N-cadherin. This presence of N-cadherin could also be due to the
incorporated fibroblasts, as this is not an endothelial-specific junctional molecule.
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Finally, we analyzed the expression of laminin in our VEGF-treated SPECs. Laminin is
an extracellular matrix component that is expressed on the abluminal walls of blood
vessels. We found that it was uniformly expressed in all constructs, regardless of
treatment.
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4.6 DISCUSSION
We have looked at how to modify the capabilities of the SPEC to create different types of
vascular patterns using growth factors. We were encouraged from our previous in vivo
data that the SPEC had reached this later stage of vessel maturation in the pipeline by 72
hours. With our recent in vitro data, incorporating the VEGFA and S1P during the
formation of the SPEC constructs, and seeing network remodeling and lumen formation,
we are excited to get these in vivo studies going in future work. We believe that SPECs
treated with exogeneous growth factors in vitro are tailorable to application-specific
demands, due to the obvious differences seen between the treatment groups. In our future
work, we plan to analyze the S1P-treated SPECs using the same markers as described
here to assess the VEGF-treated SPECs. We also want to investigate the possible
synergistic effects of these two factors by treating SPECs with both of them during the
culture period. Varying the ratio of endothelial:fibroblast cells used to create the SPEC
constructs, could elicit different results from what is reported here, so we plan to
investigate that possibility by including more endothelial cells at the time of seeding.
Finally, we plan to implement the same animal model as described in chapter three to
determine if they get perfused more quickly than the untreated SPECs once implanted.
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CHAPTER FIVE
THE SMART WOUND DRESSING
From these promising findings described in the previous chapters, we started
thinking about different applications we could apply these different technologies to. The
Yost lab has been investigating wound healing for many years and through our
collaboration with surgeons here at MUSC, we became interested in what goes wrong
during this healing process, which results in a non-healing wound. We define these nonhealing wounds as chronic wounds.
In the United States, chronic wounds account for more than $25 billion annually
in health care expenses and affect over 6.5 million people, with 85% of these patients
being 65 years and older (1-5, 34). Separate from direct healthcare expenses, an
additional $15 billion is spent on wound care products, as well as another $12 billion on
scar treatment, reaching almost $60 billion spent annually on chronic wound treatment.
Additionally, these financial estimates do not include the morbidities facing these patients
including lost work time, decreased productivity, disability payments, nor rehabilitation
costs (34).
5.1 NORMAL WOUND HEALING OF ACUTE WOUNDS
Acute wounds affect over 11 million people in the United States every year
(Singer). These wounds undergo a well-organized process of normal wound healing that
leads to predictable tissue repair. Normal wound healing is a complex, highly regulated
process that progresses through a cascade of events consisting of four temporally and
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spatially regulated phases, including coagulation, inflammation, proliferation, and
remodeling and scar formation (Demidova-Rice) (Figure 5.1).

136

Immediately after the injury occurs, platelets are activated and recruited to the
injury site where they adhere to the damaged blood vessel. When the platelets adhere to
the damaged vessel they release signaling factors, such as platelet-derived growth factor
(PDGF) and transforming growth factors A1 and A2 (TGFA1,TGFA2), that initiate a
blood-clotting cascade to prevent excess bleeding and the resultant clot provides
temporary protection for the wounded area (Figure 5.1A). The released factors stimulate
inflammatory cells, including leukocytes, neutrophils, and macrophages that then get
recruited to the wounded area and begin clearing out foreign bodies and bacteria through
the release of reactive oxygen species (D-R). This is the inflammatory phase of wound
healing, which gets resolved upon the gradual apoptosis of these inflammatory cells over
the span of a few days.
As the inflammatory phase is being resolved, the proliferative phase of tissue
repair is initiated (Figure 5.1B). The remaining inflammatory cells present at the
wounded area begin to release growth factors, as well as migratory epidermal and dermal
cells. The epidermal and dermal cells “act in an autocrine, paracrine, and juxtacrine
fashion to induce and maintain cell proliferation while initiating cellular migration” to the
site. All of these events are essential for forming granulation tissue and supporting
epithelialization of the wound area (D-R). To sustain these incoming cells an angiogenic
response is initiated to provide an adequate blood supply, which carries nutrients and
oxygen, and allows for metabolite exchange. Angiogenesis in wound healing is initiated
almost immediately after the injury occurs as the wound area becomes hypoxic. Initially,
the activated platelets release proangiogenic growth factors including vascular
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endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), and PDGF. After
the inflammatory phase, the infiltrated cells also secrete these factors, which in turn
regulate the angiogenic induction. Endothelial cells degrade their surrounding basement
membranes, so they can “migrate toward the wound site where they proliferate, form new
cell-cell contacts, and eventually new blood vessels” (D-R).
Once the new blood vessels have been formed and normal blood supply is
provided to the wounded area, epidermal and dermal cells migrate and proliferate within
this area (Figure 5.1C). The wound epithelium gets restored by the epidermal cells, while
the dermal cells, i.e. fibroblasts, secrete extracellular matrix to form granulation tissue,
mainly consisting of collagen type I, that gets perfused with the previously formed
vessels. As this occurs, a new provisional matrix consisting of collagen type III, fibrin,
fibronectin, and hyaluronic acid gradually replaces this granulation tissue. The next, and
final, phase of wound healing is wound contraction and matrix remodeling (Figure
5.1C). Wound contraction is mediated by fibroblasts that respond to platelet-released
TGFA, tissue tension, and matrix protein presentation. The fibroblasts generate actincontaining stress fibers that induces contractile forces, which are transmitted to the
surrounding extracellular matrix through focal adhesion complexes comprised of
integrins. Additionally, the matrix is continuously reorganized through slow cycles of
extracellular matrix generation and degradation, which occurs in a fibroblast-depdendent
manner (D-R). Matrix degradation occurs via matrix metalloproteases (MMPs), which
are critical regulators of the local matrix microenvironment and allow for cellular
migration, proliferation, and angiogenic induction. Once the matrix has been sufficiently
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remodeled, the fibroblasts begin to undergo apoptosis, which results in the formation of a
relatively acellular fibrotic scar (Figure 5.1C). However, even when normal wound
healing is successful, the resultant tissue can be disfigured and non-functional (35). For
example, Figure 5.2 is of a patient treated at the Medical University of South Carolina
Hospital with traditional therapies that left this patient with a non-functional tissue
associated with reduced mobility and increased morbidity for this patient.

5.2 THE CHRONIC WOUND ENVIRONMENT
Chronic wounds are wounds that have failed to progress through the normal
stages of wound healing (Figure 5.3). These wounds characteristically have an
accumulation of metabolic waste products, proteins, and enzymes in the affected area,
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leading to excess wound exudate. Chronic wound exudate inhibits fibroblast proliferation
and contains proteases that degrade extracellular matrix and growth factors.

Chronic wounds are also associated with high levels of pro-inflammatory
cytokines, which have been shown to inhibit growth and induce morphological changes
in normal skin fibroblasts, as well as arrest the healing process in the inflammatory state
(4). Fibroblasts in chronic tissue appear larger and polygonal, tend to be non-responsive
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to growth factor stimulation, and have reduced mobility and migration as compared to
normal healing tissues. The irregularities of the predominant extracellular matrixproducing cells lead to a compositional change in the structural environment, such as
decreased production of laminin, fibronectin, collagen, as well as others, and inadequate
matrix reorganization. Chronic inflammation can lead to endothelial cell dysfunction and
impaired blood vessel regeneration. Bacteria are present on virtually all open wounds.
Bacterial colonization occurs when the growth and death of microbes are kept in balance
by the host immune system. When host defenses can no longer maintain this balance, the
wound enters a non-healing, infected state. If the infection goes untreated, and turns
systemic, the infected area may have to be amputated for patient survival. For example,
the C. gas gangrene infection shown in Figure 5.3D of a patient treated at the Medical
University of South Carolina hospital resulted in a lower right limb amputation due to the
extent of the infection. From our literature search, we came up with a list of the major
players contributing to impaired wound healing in these chronic wounds (Figure 5.4).
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5.3 PRESSURE ULCERS
Pressure ulcers, one of the most frequently observed chronic wounds in clinics,
develop when an area of skin is placed under constant pressure for an extended period of
time resulting in tissue ischemia, depletion of nutrients and oxygen supply to site, and
eventually tissue necrosis (Osuala). When an area of skin is exposed to prolonged
pressure, blood vessels within the distorted tissue are occluded and blood is unable to
flow. While ischemia is the initiator of pressure ulcer formation, there are other
underlying factors involved in the failure of these wounds to heal.
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Pressure ulcers are classified as Stage 1 if the skin remains unbroken, but there is
evident inflammation at the site with the area appearing red and warm (Figure 5.5A).
Stage 2 pressure ulcers have partial-thickness loss of the epidermis, the outermost layer
of the skin, and some of the dermis, however no slough is present (Figure 5.5B). Slough
is soft, moist, avascular, dead tissue. Stage 3 ulcers are characterized by full-thickness
skin loss, including epidermis and dermis, and necrosis of subcutaneous tissue (Figure
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5.5C). Slough and necrotic tissue, as well as undermining and tunneling, may be visible,
however, no underlying muscle, bone, or tendon is exposed (Figure 5.5E). Undermining
is caused by erosion under the wound edges, resulting in a large wound with a small
opening. Tunneling is a secondary wound caused by a high volume of pressure being
forced upon many tissue layers, which can prompt the layers to become less voluminous
than surrounding tissues, creaking a sinkhole-like effect in the skin. Pressure ulcers
progress to Stage 4 when there is full-thickness skin loss including the epidermis, dermis,
and subcutaneous tissue (Figure 5.5D). Underlying muscle, bone, and tendon may be
visible, as well as slough, undermining, and tunneling.
5.4 TRADITIONAL WOUND TREATMENT
Wound dressing devices are a vital component in the treatment of chronic, nonhealing wounds. The traditional dressings predominantly used in clinics are shown in
Figure 5.6. Plain dry gauze has historically been one of the most popular wound
dressings. Gauzes have good absorptive properties, but can completely dehydrate the
wound, which is detrimental to wound healing. They also tend to adhere to the wound
surface and removal can be painful and traumatic. Due to their absorptive properties, they
have limited ability to provide an effective barrier against bacterial invasion.
Hydrocolloids are adhesive, occlusive (do not permit gas or fluid flow) dressings that
absorb wound exudate to form a hydrophilic gel that helps maintain a moist healing
environment. They provide protection against shear force at the skin surface. However,
these dressings have risk of periwound maceration and, if the site gets too moist, may
separate from the wound bed, requiring frequent dressing changes. Maceration occurs
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when the healthy tissues surrounding the wound bed, i.e. the periwound, are exposed to
excess moisture and begin to degrade, which can further impede wound healing, as well
as lead to increased deterioration of the wound bed (31). Hydrogels are water-based
materials that help maintain a moist environment. They can be applied and removed
without causing pain or further trauma. Additionally, patients have reported pain relief
with these dressings, likely due to their cooling effects. Foams are semi-occlusive
dressings that provide thermal insulation and protect against shear. They are nonadhesive, so there is no tissue injury or pain associated with dressing changes. However,
foams have no protective barrier to prevent bacterial contamination and, like
hydrocolloids, may promote development of excessive wound exudate requiring frequent
dressing changes.
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Traditional dressings fall short in addressing the three main issues that impede
healing: preventing bacterial infection, ineffective inducement of cell migration and
neovascularization, as well as maintenance of wound moisture balance and control of
wound exudate. Additionally, standard of care techniques, for example wet-to-dry
dressings, are labor intensive and can induce secondary injury and pain to the patient.
5.5 MODERN WOUND TREATMENT
Advanced wound dressings such as TriTech Silver and Apligraf®, a bi-layered
cultured skin substitute, require numerous applications and have been unsuccessful in
adequately closing chronic wounds (7,15,18-19). Tritec Silver® is a bi-layered device
comprised of a Protective Layer and a Transfer Layer (Figure 5.7).

The layer proximal to the wound is the Protective Layer, which supports two critical
functions: regulating moisture and protecting surrounding healthy skin and underlying
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tissues. The layer is designed with unidirectional fibers that only wick moisture vertically
through the dressing and away from the wound bed. The top or transfer layer is composed
of highly hydrophilic fiber that pulls exudate through the protection layer, away from the
wound, and into a secondary dressing (i.e. gauze). This layer prevents accumulation of
wound exudate. In addition, this dressing has a silver antimicrobial technology that
releases silver ions when exposed to sodium-containing fluid, like wound exudate. While
this product targets some of the contributors of wound healing, it has been met with
limited success in case studies, and must be used in combination with other treatments,
like compression therapy (15).
Apligraf is a bi-layered skin substitute comprised of cells and collagen (Figure
5.8). It is currently the only FDA-approved cell-based treatment for venous and diabetic
ulcers (18).
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The dermal layer combines a type I collagen matrix and human fibroblasts, which secrete
additional matrix produces. The epidermal layer is formed from keratinocytes, which
proliferate and differentiate to replicate the in vivo architecture. While Apligraf has
shown promising results for the healing of acute wounds (Figure 5.8B), studies in
chronic wounds found the graft did not persist long enough for therapeutic effects
(18,19). This dressing also must be used with a secondary dressing, and is not a singleapplication treatment option.
5.6 THE SMART WOUND DRESSING (SWOD)
When we started thinking about how to design a single device that can address all
of the major players contributing to impaired wound healing, we reverted back to what
the ancient Egyptians were doing in ~2000 B.C. They created combinatorial devices
comprised of lint to address the excess wound exudate, animal grease to provide a
hydrophobic barrier and protect the wound bed from the external environment, and
honey, which has inherent antibacterial properties due to its osmolarity. In doing so, we
realized there was no single material that could successfully provide all of these features
(Figure 5.4), and began developing a multi-layered wound dressing, the Smart Wound
Dressing (SWOD). The SWOD is a multi-component device made up of three separate
layers that individually address different facets of the chronic wound environment
(Figure 5.9).

148

The bottom layer of the SWOD, the anti-inflammatory layer, serves a dual
function, first providing a provisional matrix to host cell migration, and second to
regulate moisture balance in the wound bed. This layer was designed to address the
deficiency in extracellular matrix proteins and provisional matrix in chronic wounds, and
act as a scaffold for cell adherence and subsequent matrix deposition. Electrospun
collagen was chosen because it has previously been reported to improve wound healing
(27). The reaction electrospun collagen fibers are created using a novel technique
developed in the Yost Lab at the Medical University of South Carolina. This technique
produces a superior fibrous scaffold that is unique in its resistance to trypsin digestion,
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and as produced, these fibers can donate or absorb water from the wound bed to maintain
a moisture content equivalent to that found in healthy skin (22).
The middle layer of the SWOD, the living component, has been incorporated to
promote revascularization and angiogenesis at the wound site. This layer incorporates
endothelial cells and fibroblasts to overcome the irregularities associated with these cell
types in chronic wounds. These constructs have been engineered to contain a prevascular
bed and supply reparative fibroblasts (21,28). This layer serves to provide cues to
encourage migration and repopulation of the wound bed with viable host cells and
promote revascularization to the site. Additionally, when implanted into the hind limb of
a rat, the SPEC was shown to rapidly integrate with the surrounding host vasculature
within 6 hours of implantation. Figure 5.10 shows that there is distinct overlap of the
implanted cells, shown in Cell Tracker+ blue, coinciding with vasculature marker (vWF)
that is labeling both the human implanted and the host rat vascular components.
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Finally, the external side is composed of hydrophobic silver coated woven polyester
and an internal membrane of 0.1𝜇m pore size, hydrophilic polytetrafluoroethylene (PTFE).
The amphipathic nature of this layer creates a unidirectional flow of exudate out of the
wound bed, thereby creating an appropriate environment that promotes regeneration, while
preventing accumulation of excess wound exudate. In addition, the hydrophobic outer
silver coating kills invading pathogens and provides an added layer of protection against
infection (23). During the development of this layer many materials were investigated
including regenerated cellulose, polysulfone, polycarbonate membranes, among others.
Hydrophilic PTFE proved to be the best option for the SWOD, and has been widely used
in medical applications, such as vascular grafts and surgical meshes (24-26). Its hydrophilic
nature prevents protein binding, and subsequent cell or bacteria adherence, while
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permitting the filtration of fluid. The combination of these product features specifically
targets the issues encountered in treating and closing these difficult wounds.
The Smart Wound Dressing (SWOD) is unique in its multifaceted approach which
minimizes bioburden, while reviving normal wound healing mechanisms by increasing
cellular migration, facilitating angiogenesis, and controlling moisture balance in the wound
bed. The scientific premise of this project is that the overlapping functions of these layers
combine to create a superior treatment by attenuating the multiple contributors to failed
healing as compared to standard of care. The SWOD is a single application device, and its
development will accelerate closure, shorten hospital stays, and reduce costs associated
with chronic wounds. We believe that this combinatorial approach, which actively targets
all of the contributors to impaired wound healing, will provide an exciting new option for
the treatment of chronic wounds.
5.7 METHODS
Electrospinning Apparatus and Methods
The electrospinning technology was developed and previously described by the Yost Lab
at the Medical University of South Carolina (Figure 5.11; Patent Filed; 22).

152

Sputter-coating of Woven Polyester Membranes
The top portion of the external layer comprises a woven polyester material with one side
sputter-coated with silver using a Cressington 180 Auto/SE apparatus. In preliminary
work we determined the optimal parameters for silver deposition across the entirety of
the sample to be 30mA for 150 seconds for uniform coating.
Total Silver-Loading Measurements
Sputter-coated samples were analyzed for silver concentration using flame atomic
absorption spectrometry (FAAS). Total ash from each membrane was measured and
reported as a percentage of the starting weight of the material. Both the silver-coated
woven polyester and the hydrophilic 0.1𝜇m PTFE membranes were imaged with
scanning electron microscopy.
Hydrophobicity of Silver-coated Woven Polyester
The hydrophobicity of silver sputter-coated samples will be determined by contact angle
measurements. Each side (A,B) of the polyester material was sputter-coated in silver for
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one cycle (30mAmps for 150 seconds). The samples were placed on a level surface and a
12𝜇L drop of distilled water was deposited on top of it. Side-view images of the drops
and a length reference scale were captured. The measurements required for analyzing the
contact angles were taken and recorded in CellSens. Drop shape analysis was performed
LCB1LH

using the formula: Contact Angle = 2tan%& (-./ MI?C) for quantifying the contact angles.
Bulk Absorption
The bulk absorption properties of the top layer of the SWOD was measured following the
standard method (31). Silver-coated or plain woven polyester samples were cut into 22
mm discs and the initial weight of each dressing was recorded. The samples were then be
placed in a cup of simulated wound fluid (142mM NaCl, 2.5mM CaCl# in DI H# O) and
incubated at 37℃ in humidity for 30 minutes. Two marketed products, Gauze and CVS
non-stick pads, were used as controls. The samples were removed from the solution and
hung vertically for 30 seconds to remove any excess fluid. Finally, the sample was
weighed to determine the final weight. Bulk absorption was calculated as:
Bulk Absorption =

NBFI4 "CB1LH%OFBHBI4 "CB1LH
PECI 3Q RI!S4C

(

1
!"

). This was performed in triplicate.

Antimicrobial Properties of Silver-coated Woven Polyester Membrane
Ubiquitous opportunistic microorganisms readily occupy the site of an open wound. The
presence of these microorganisms above a specific bacterial load exacerbates the already
unresolved inflammatory response. An antibacterial layer that preemptively excludes
these organisms will improve our ability to accelerate closure. To assess the antimicrobial
properties of our silver-coated woven polyester membrane, we performed a Kirby-Bauer
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assay using three frequently seen bacteria in clinics, including MSSA, MRSA, and E.
Coli.
Cytotoxicity of SWOD Components
The woven polyester membrane with and without a silver-coating were analyzed
separately to assess cytotoxicity of the material. Samples were submerged in supplementfree Endothelial Growth Medium (EGM) and incubated for 2, 8, or 14 days. Human
adipose microvascular endothelial cells were cultured to confluence in a 96-well plate,
and a 1:1 supernatant extract to EGM-2 volume (i.e. 100𝜇L supernatant and 100𝜇L
EGM-2 per well) was added to the endothelial cells for 24 hours. At 24 hours,
AlamarBlue was added at 10% total volume and incubated for 3 hours. During this
incubation, the cells metabolize the blue non-fluorescent dye to red fluorescent resorufin.
A microplate reader was used to measure fluorescence at an excitation length of 535 nm
and emission of 590 nm.
Moisture Content of Reaction Electrospun Collagen Fibers
A piece of aluminum foil was weighed. Reaction electrospun collagen fibers were added
to the aluminum foil, and excess water was removed using a Kim Wipe. The wet weights
of the fibers were recorded, and the fibers were placed in an oven overnight. The dry
weights of the collagen fibers were recorded, and the moisture content was determined
8EG "CB1LH

from the amount of protein: Protein(%) = "CH "CB1LH × 100%.
Formation of Scaffold-free Prevascularized Endothelial-fibroblast Constructs and
Fibroblast-only Spheroids (FOS)
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The scaffold-free prevascularized endothelial-fibroblast constructs were created as
described previously in chapter 3. Briefly, a high-density cell suspension of 1:4 human
adipose microvascular endothelial cells (HAMEC, ScienCell) and normal human dermal
fibroblasts (NHDF, Lonza) were seeded in a non-adherent agarose mold and cultured for
three days. The rod-shaped SPEC with dimensions of 1 mm wide by 6 mm long, required
9x105 total cells. For controls, fibroblast-only spheroids (FOS) were formed from 9x105
NHDF.
Incorporation of Reaction Electrospun Collagen Fibers with SPEC
Crosslinked collagen fibers were placed in the bottom of the SPEC agarose mold. 7.2e/
Normal Human Dermal Fibroblasts (NHDF) and 1.8e/ Human Adipose Microvascular
Endothelial Cells (HAMEC) were seeded onto the fibers, and cultured for 3 days in order
to validate that the SPEC will incorporate the collagen fibers when cultured together, and
that the SPEC will retain its prevascular networks with surrounding matrix deposition.
Drug Incorporation in Reaction Electrospun Collagen Fibers and Drug (JM-2)
Release Kinetics
The JM-2 peptide, denoted “P” in Figure 5.9, targets the microtubule-binding domain of
connexin 43 hemichannels and was shown to prevent the release of cytoplasmic ATP into
extracellular space, resulting in reduced inflammation and improved wound healing
(Figure 5.12; Calder). We wanted to investigate the possibility of using the reaction
electrospun collagen fibers as a drug delivery mechanism to improve wound healing in
chronic wounds.
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The 1% collagen fibers (wet) were UV-crosslinked with 6.3e/ D!" . The JM-2 peptide was
incorporated by dip coating 1.5 g crosslinked collagen fibers (wet) in buffer containing
180𝜇M of JM2 in a 12-well plate, and shaking for two hours at 4℃. The supernatant was
removed and the fibers were placed in Eppendorf tubes, and stored in the -20℃ freezer. 1
mL Dulbecco’s phosphate-buffered saline (+Ca, +Mg) was added to each well, and the
fibers were incubated for 1 hour at 37℃. After 1 hour, the supernatant was removed and
placed in Eppendorf tube, and stored in the -20℃ freezer. A fresh 1 mL PBS (+Ca, +Mg)
was added. This was repeated at times 1, 2, 5, 17, 20, and 24 hours. The supernatants
were then in -20℃ freezer until ready for use. We hypothesize that the UV-crosslinking
will not impact drug release from the reaction electrospun collagen fibers, and that these
fibers will serve as an adequate vehicle for drug delivery for our application.
Invasion Assay
A zone of exclusion was created in each well of a 12-well plate by placing a sterile 5 mm
silicone disc on the bottom center of a culture well and seeding a monolayer of 5,000
normal human dermal fibroblasts. After 3 days, and once the surrounding, perimeter
fibroblasts had reached ~75% confluence, they were stained with Cell Tracker Deep Red
following the kit instructions. The silicone discs were removed, and a SPEC was placed

157

in the center of the excluded area (Figure 5.13). An avascular fibroblast-only spheroid
(FOS) was used as a control to determine the effects of having a prevascularized structure
present on recruiting cell migration. The BioTek LionHeart FX Automated Live Cell
Imaging Microscope was used to record cell migration over 7 days. This was performed
in triplicate and analyzed using regression analysis for the time series data.

Development of an in vivo Murine Pressure Wound Model
For future in vivo studies to assess the functionality of the SWOD to heal pressure
wounds, the Yost lab has created a murine pressure wound model by compressing full
thickness tissue between a magnet and steel plate for 48 hours.
5.8 RESULTS
Reaction Electrospun Collagen Fibers
Electrospinning, a technique developed at the Yost lab, is capable of recreating collagen
fibers that closely resemble the in vivo niche (22; Figure 5.14). Here we have
demonstrated that the collagen fibers produced with this technique retain the native
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collagen molecular structure and mechanical properties that are tunable to the in vivo
elastic modulus (Figure 5.14; 22).
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Total Silver-Loading Measurements
The total amount of silver deposited on the woven polyester membranes using
Cressington 180 Auto/SE apparatus at 30 mAmp for 150 seconds was 0.12%. Figure
5.15 shows scanning electron microscopy images of the silver-coated woven polyester
and the hydrophilic 0.1µm PTFE membranes.

Hydrophobicity of Silver-coated Woven Polyester
The contact angles were measured for each side (n=8). The average contact angles were
133.37 ± 6.62° and 134.45 ± 4.48° for side A and B, respectively, with no significant
difference between the two sides (Figure 5.16, P>0.5). Both sides were sufficiently
hydrophobic for our application, as indicated by contact angles greater than 90°.
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Bulk Absorption

161

The bulk absorption of the standard 12-ply gauze and the CVS Non-stick pads were
significantly higher than the woven polyester with and without silver-coating (Figure
1

5.17). The woven polyester materials were still able to absorb 500 !" of simulated wound
fluid. While our materials absorbed less fluid than the marketed products, this may
actually be advantageous because the other products can actually become to moist and
induce maceration, the degradation of healthy surrounding tissues due to excess fluid
exposure, which could actually increase the size of the wound and lead to more trauma.

Antimicrobial Properties of Silver-coated Woven Polyester Membrane
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To determine if the top layer is actively antimicrobial, we ran a bacterial colonization
assay. We determined its bacterioscidal and had a zone of exclusion of 150 microns. We
were very happy to see these results specifically with MRSA as this is an antibioticresistant type of bacteria often seen in clinical settings.

Cytotoxicity of SWOD Components
Our analysis of cell toxicity indicated that the woven polyester was not toxic to
endothelial cells (Figure 5.19). Importantly, the silver-coating did not hinder their
viability, which was a concern during the development of this layer. Therefore, we
believe we have the appropriate material, and have determined the appropriate silverloading, to act as an antibacterial, while permitting endothelial cell survival and
functionality.
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Moisture Content of Reaction Electrospun Collagen Fibers
We theorize that it will also help maintain a moist wound environment by donating or
absorbing water molecules to the wound surface. The moisture content of reaction
electrospun collagen fibers was found to be 97.59 ± 0.33% and 97.50 ± 0.58% for
0.75% and 1.5% collagen fibers, respectively (0.5<P<0.2, not significant; Figure 5.20).
As produced, these fibers have an average moisture content of 97.54% with the water
bound to the collagen. As there were no significant differences between these two
collagen concentrations, we are not limited to a specific collagen concentration, and a
variety of collagen fibers could be used for the treatment of these wounds.
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Incorporation of Reaction Electrospun Collagen Fibers with SPEC
SPECs were fixed and labeled with F-actin (Phalloidin, green), endothelial networks
(CD-31, red), and nuclei (Hoescht, blue) to validate the formation of prevascular
networks when reaction electrospun collagen fibers were incorporated during the
incubation period (Figure 5.21). The SPEC cultured with the collagen fibers retained the
prevascular network, as well as adequate extracellular matrix production, indicating
successful integration with one another. This data also suggests that the reaction
electrospun collagen fibers will provide a scaffold for cell migration.
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Drug Incorporation in Reaction Electrospun Collagen Fibers and Drug (JM-2)
Release Kinetics
Our Western Blot analysis of the JM-2 released from the reaction electrospun collagen
fibers demonstrated that the method of incorporating the drug, UV-crosslinking, did not
affect its release, and showed that the majority of the drug was released within the first
two hours (Figure 5.22). Therefore, we believe the reaction electrospun collagen fibers
serve as adequate vehicles for drug delivery. A multitude of other drugs, such as
vancomycin, etc., and/or signaling factors, i.e. VEGF, PDGF, etc., could be incorporated
into the RES collagen fibers.
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Invasion Assay
By 24-48 hours cells are actively migrating out of both the SPEC and FOS into the
surrounding exclusion zone. By day 4 the surrounding healthy fibroblasts (indicated by
yellow staining) had migrated across the zone of exclusion and integrated with both the
SPEC and FOS constructs. By day 10 (not pictured) we had a monolayer of cells
remaining. This was really exciting because it indicates the SPEC can re-establish cell
communication and migration across wound area. Additionally, the SPEC provides
endothelial cells, which can contribute to angiogenesis and new blood vessel formation,
as well as fibroblasts that will secrete extracellular matrix and help stabilize newly
formed vessels in the area.
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SWOD Assembly
To ensure all of the components of the SWOD can be successfully integrated and
assembled into a single device, we have developed the prototype shown in Figure 5.24.
We were able assemble all of the components, and in the future will be able to tailor the
device depending on wound depth and the presence of tunneling and undermining in
order to treat the entire wound area.
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Development of an in vivo Murine Pressure Wound Model
Figure 5.25A shows the successful creation of a pressure wound created by compressing
full thickness tissue between an implanted steel plate and a magnet for 48 hours. The
wound is approximately 8 mm on the long axis and 1.5 mm deep. There is an eschar in
the wound that will be removed and the wound debrided prior to application of wound
care technology. Figure 5.25B shows a hematoxylin and eosin stained section of the
same wound in A, which highlights the loss of skin tissue, the necrotic muscle tissue and
a fragment of the eschar. Figure 5.25C is an image of a full-thickness acute wound
created using an 8mm biopsy punch, and Figure 5.25D is a hematoxylin and eosinstained section of the wound from C, showing the loss of tissue from the creation of the
wound. We believe that these two models will serve as useful platforms for testing the
SWOD in vivo.
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5.9 DISCUSSION
Described here is a novel wound healing device that successfully targets all facets
contributing to the impaired wound healing observed in chronic wounds. We have
demonstrated in in vitro studies that the woven polyester layer sputter-coated for 100s at
150 mAmp, applying 0.12 wt% silver, is bactericidal to S. aureus MSSA and MRSA, E.
coli, and E. faecalis and also non-toxic to cultured endothelial cells. Additionally, we
have shown that the reaction electrospun collagen fibers have the appropriate moisture
content for the wound area, and that they can serve as a provisional matrix for cells. The
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reaction electrospun collagen fibers were able to be incorporated into the cellular
component of the SWOD, the SPEC layer, during the three-day culture period, and were
shown to be adequate vehicles for drug delivery, specifically JM-2, for this application.
We were able to successfully assemble all of the components of the SWOD to create a
prototype, and developed adequate animal models for testing this product in vivo for
future studies. We believe the SWOD will perform superiorly to other marketed devices,
and accelerate the time it takes chronic wounds to heal. Finally, the SWOD is novel in
that it is a single-application device, which will reduce healthcare costs and morbidity
associated with dressing changes seen with other devices.
Future Possibilities of Generating a Patient-Specific SWOD
Current treatments for chronic wounds, including pressure ulcers, are standardsized gauzes, films, and casts. There is no product that comes in patient-derived sizes, as
even Apligraf® comes in standard sizes. During the treatment of these wounds, it is
essential for a clinician to consistently check the wound progression, which is often done
with imaging. 3D ultrasound (3D-US) has previously been used to image pressure ulcers
as a prognostic indicator (41). These images can be used to produce volume-rendered 3D
images for determination of the volume of a wound area. The MakerBot Replicator 2, a
plastic 3D printer, can generate scaffolds with a resolution of 400𝜇m. With this
technology, it is possible to take patient images and reproduce a 3D model. We have
previously obtained CT images from a pediatric patient at MUSC suffering from
craniosynostosis. Amira was used to convert the patient CT scans into CAD designs for
use in surgical planning. The architecture of the models rendered were measured and
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compared to the original scans to assess the resolution of this method. The plastic skulls
were mimetic of the in vivo condition (Figure 5.26, Table 5.1).

We can also incorporate these patient scans for use with the Palmetto Printer as
discussed in chapter two to create patient-mimetic constructs. Figure 5.27 shows reaction
electrospun collagen fibers serving as a substrate for cell printing, as could be used for
creating the SWOD.
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We have further expanded on methods for developing patient-specific dressings
through the use of a novel imaging technique we have patented. The scanner is a multicamera system that uses structured light to calculate the dimensions and architectures of
three-dimensional soft objects (Figure 5.28A). We are unique in having the capability of
being able to recapitulate soft tissue areas with high fidelity, as demonstrated by this scan
of an abdominal wound of an MUSC patient (Figure 5.28B). This technology can help us
determine the depth of the wound, and how much collagen we would need, as well as the
overall size of the SWOD dressing, allowing us to determine the number of SPEC
constructs needed, as well as the other components. Additionally, these scans could be
converted into bioprinter-compatible software and we could mimic a deficit as needed.
This technology it is not limited to the creation of Smart Wound Dressings, but could also
be used for many other tissue engineering applications.
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In addition to developing patient-mimetic wound scaffolds with respect to
structure, we have the technology to produce autologous cellular constructs (i.e. the
SPEC component). In clinic, autologous cells could be harvested from the patient’s
adipose tissue, and grown in culture. To generate patient-specific constructs, the wound
scaffold could be created from patient images rendered into computer-aided design
software and fabricated using a 3D bioprinter, specifically the Palmetto Printer, and
subsequently seeded with cells (i.e. indirect bioprinting). The Palmetto Printer has three
dispensers and is able to concurrently deposit heterogeneous materials and cell types. We
have previously characterized the bioprinter for cell viability, reproducibility, and its
ability to generate constructs in complex architectures.
The most critical aspect of developing these novel technologies, especially those
including cellular components, is the translational feasibility of actually being able to
implement them in clinics. The following SWOD production timeline has been
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developed, and has promising translatability due to the availability of the required cell
types, as well as the short culture time periods.
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